Abnormal	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65-RelA	B-protein
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	B-protein
receptor	I-protein
-initiated	O
signaling	O
events	O
and	O
lymphokine	B-protein
production	O
.	O

Because	O
NF-kappa	B-protein
B	I-protein
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	B-DNA
genes	I-DNA
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
complex	I-protein
in	O
lupus	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Freshly	O
isolated	O
T	B-cell_type
cells	I-cell_type
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	B-protein
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
Abs	I-protein
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane-mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

When	O
compared	O
with	O
normal	B-cell_type
cells	I-cell_type
,	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Also	O
,	O
NF-kappa	B-protein
B	I-protein
activity	O
remained	O
absent	O
in	O
follow-up	O
studies	O
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	B-protein
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF-kappa	B-protein
B	I-protein
activity	O
,	O
p65	B-protein
complexes	I-protein
were	O
not	O
formed	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B-protein
protein	I-protein
levels	O
.	O

As	O
p65	B-protein
complexes	I-protein
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	B-protein
cytokine	I-protein
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Flexible	NULL
,	NULL
Intuitive	NULL
,	NULL
and	NULL
Luminex	NULL
.	NULL

C4	NULL
-	NULL
«	NULL
gf\	NULL
_	NULL
}	NULL
Affordable	NULL
Cytometry	NULL
,	NULL
warmmore	NULL
complexity	NULL
simplified	NULL
.	NULL

Guava®	NULL
easyCyte	NULL
``	NULL
Flow	NULL
Cytometers	NULL
.	NULL

#	NULL
m	NULL
meJournal	NULL
of	NULL
Abnormal	NULL
NF-KB	NULL
Activity	NULL
in	NULL
T	NULL
Lymphocytes	NULL
...	NULL
<	NULL
f'Immun010	NULL
gy	NULL
from	NULL
Patients	NULL
with	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
Is	NULL
Associated	NULL
with	NULL
Decreased	NULL
p65-RelA	NULL
Protein	NULL
Expression	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Henry	NULL
K.	NULL
Wong	NULL
,	NULL
Gary	NULL
M.	NULL
Kammer	NULL
,	NULL
Greg	NULL
Dennis	NULL
and	NULL
George	NULL
C.	NULL
Tsokos	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
163:1682-1689	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/163/3/1682	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
43	NULL
articles	NULL
,	NULL
20	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/163/3/1682	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Abnormal	NULL
NF-rB	NULL
Activity	NULL
in	NULL
T	NULL
Lymphocytes	NULL
from	NULL
Patients	NULL
with	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
Is	NULL
Associated	NULL
with	NULL
Decreased	NULL
p65-RelA	NULL
Protein	NULL
Expression	NULL
``	NULL
Henry	NULL
K.	NULL
Wong	NULL
,	NULL
**	NULL
Gary	NULL
M.	NULL
Kammer	NULL
,	NULL
``	NULL
Greg	NULL
Dennis	NULL
,	NULL
``	NULL
and	NULL
George	NULL
C.	NULL
Tsokos***	NULL
Numerous	NULL
cellular	NULL
and	NULL
biochemical	NULL
abnormalities	NULL
in	NULL
immune	NULL
regulation	NULL
have	NULL
been	NULL
described	NULL
in	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
(	NULL
SLE	NULL
)	NULL
,	NULL
including	NULL
surface	NULL
Ag	NULL
receptor-initiated	NULL
signaling	NULL
events	NULL
and	NULL
lymphokine	NULL
production	NULL
.	NULL

Because	NULL
NF-KB	NULL
contributes	NULL
to	NULL
the	NULL
transcription	NULL
of	NULL
numerous	NULL
inflammatory	NULL
genes	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
molecular	NULL
target	NULL
of	NULL
antiinflammatory	NULL
drugs	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
characterize	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
the	NULL
NF-xB	NULL
protein	NULL
complex	NULL
in	NULL
lupus	NULL
T	NULL
cells	NULL
.	NULL

Freshly	NULL
isolated	NULL
T	NULL
cells	NULL
from	NULL
lupus	NULL
patients	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
RA	NULL
)	NULL
patients	NULL
,	NULL
and	NULL
normal	NULL
individuals	NULL
were	NULL
activated	NULL
physiologically	NULL
via	NULL
the	NULL
TCR	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
Abs	NULL
to	NULL
assess	NULL
proximal	NULL
membrane	NULL
signaling	NULL
,	NULL
and	NULL
with	NULL
PMA	NULL
and	NULL
a	NULL
calcium	NULL
ionophore	NULL
(	NULL
A23187	NULL
)	NULL
to	NULL
bypass	NULL
membrane-mediated	NULL
signaling	NULL
events	NULL
.	NULL

We	NULL
measured	NULL
the	NULL
NF-KB	NULL
binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
by	NULL
gel	NULL
shift	NULL
analysis	NULL
.	NULL

When	NULL
compared	NULL
with	NULL
normal	NULL
cells	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
NF-KB	NULL
activity	NULL
in	NULL
SLE	NULL
patients	NULL
was	NULL
significantly	NULL
decreased	NULL
in	NULL
SLE	NULL
,	NULL
but	NULL
not	NULL
in	NULL
RA	NULL
,	NULL
patients	NULL
.	NULL

NF-xB	NULL
binding	NULL
activity	NULL
was	NULL
absent	NULL
in	NULL
several	NULL
SLE	NULL
patients	NULL
who	NULL
were	NULL
not	NULL
receiving	NULL
any	NULL
medication	NULL
,	NULL
including	NULL
cortico-steroids	NULL
.	NULL

Also	NULL
,	NULL
activity	NULL
remained	NULL
absent	NULL
in	NULL
follow-up	NULL
studies	NULL
.	NULL

In	NULL
supershift	NULL
experiments	NULL
using	NULL
specific	NULL
Abs	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
,	NULL
in	NULL
the	NULL
group	NULL
of	NULL
SLE	NULL
patients	NULL
who	NULL
displayed	NULL
undetectable	NULL
NF-KB	NULL
activity	NULL
,	NULL
p65	NULL
complexes	NULL
were	NULL
not	NULL
formed	NULL
.	NULL

Finally	NULL
,	NULL
immunoblot	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
showed	NULL
decreased	NULL
or	NULL
absent	NULL
p65	NULL
protein	NULL
levels	NULL
.	NULL

As	NULL
p65	NULL
complexes	NULL
are	NULL
transcriptionally	NULL
active	NULL
in	NULL
comparison	NULL
to	NULL
the	NULL
p30	NULL
homodimer	NULL
,	NULL
this	NULL
novel	NULL
finding	NULL
may	NULL
provide	NULL
insight	NULL
on	NULL
the	NULL
origin	NULL
of	NULL
abnormal	NULL
cytokine	NULL
or	NULL
other	NULL
gene	NULL
transcription	NULL
in	NULL
SLE	NULL
patients	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
163	NULL
;	NULL
1682-1689.	NULL
bnormalities	NULL
in	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
described	NULL
in	NULL
patients	NULL
A	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
(	NULL
SLE	NULL
)	NULL
*	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Studies	NULL
have	NULL
identified	NULL
molecular	NULL
defects	NULL
that	NULL
include	NULL
:	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
calcium	NULL
flux	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
ligation	NULL
(	NULL
3	NULL
)	NULL
,	NULL
aberrant	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
abnormal	NULL
cAMP	NULL
regulation	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Additional	NULL
aberrations	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
cell	NULL
surface	NULL
molecule	NULL
expression	NULL
,	NULL
such	NULL
as	NULL
CD40	NULL
ligand	NULL
(	NULL
L	NULL
)	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
FasL	NULL
(	NULL
10	NULL
)	NULL
,	NULL
defective	NULL
cytotoxic	NULL
cell	NULL
function	NULL
(	NULL
11	NULL
)	NULL
,	NULL
TGF-B	NULL
production	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Another	NULL
defect	NULL
that	NULL
has	NULL
been	NULL
well	NULL
described	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
the	NULL
deficient	NULL
synthesis	NULL
of	NULL
IL-2	NULL
when	NULL
T	NULL
cells	NULL
are	NULL
stimulated	NULL
by	NULL
mitogens	NULL
(	NULL
14-17	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
for	NULL
this	NULL
defect	NULL
at	NULL
the	NULL
molecular	NULL
level	NULL
remains	NULL
unclear	NULL
.	NULL

IL-2	NULL
production	NULL
is	NULL
regulated	NULL
predominantly	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
and	NULL
requires	NULL
signaling	NULL
through	NULL
the	NULL
TCR	NULL
and	NULL
the	NULL
CD28	NULL
costimulatory	NULL
molecule	NULL
(	NULL
18-22	NULL
)	NULL
.	NULL

Transcription	NULL
factors	NULL
that	NULL
participate	NULL
in	NULL
inducing	NULL
the	NULL
synthesis	NULL
of	NULL
IL-2	NULL
mRNA	NULL
include	NULL
:	NULL
Departments	NULL
of	NULL
*Cellular	NULL
Injury	NULL
and	NULL
Medicine	NULL
,	NULL
Walter	NULL
Reed	NULL
Army	NULL
Institute	NULL
of	NULL
Research	NULL
,	NULL
Washington	NULL
,	NULL
DC	NULL
20307	NULL
;	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
Uniformed	NULL
Services	NULL
University	NULL
of	NULL
the	NULL
Health	NULL
Sciences	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20814	NULL
;	NULL
*Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
Wake	NULL
Forest	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Winston-Salem	NULL
,	NULL
NC	NULL
27157	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
March	NULL
1	NULL
,	NULL
1999	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
May	NULL
14	NULL
,	NULL
1999	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
study	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
Walter	NULL
Reed	NULL
Army	NULL
Medical	NULL
Center	NULL
Department	NULL
of	NULL
Cellular	NULL
Injury	NULL
work	NULL
unit	NULL
no.1829	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
ROL	NULL
Al42269	NULL
.	NULL

2	NULL
The	NULL
opinions	NULL
and	NULL
assertions	NULL
contained	NULL
herein	NULL
are	NULL
the	NULL
private	NULL
views	NULL
of	NULL
the	NULL
authors	NULL
and	NULL
are	NULL
not	NULL
to	NULL
be	NULL
construed	NULL
as	NULL
official	NULL
or	NULL
reflecting	NULL
the	NULL
views	NULL
of	NULL
the	NULL
Department	NULL
of	NULL
the	NULL
Army	NULL
or	NULL
the	NULL
Department	NULL
of	NULL
Defense	NULL
.	NULL

°	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
George	NULL
C.	NULL
Tsokos	NULL
,	NULL
Department	NULL
of	NULL
Cellular	NULL
Injury	NULL
,	NULL
Walter	NULL
Reed	NULL
Army	NULL
Institute	NULL
of	NULL
Research	NULL
,	NULL
Bldg	NULL
40-3078	NULL
,	NULL
Washington	NULL
,	NULL
DC	NULL
20307	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
gtsokos	NULL
@	NULL
usa.net	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
SLE	NULL
,	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
;	NULL
L	NULL
,	NULL
ligand	NULL
;	NULL
RA	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
AP-1	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
NF-KB	NULL
(	NULL
19	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Although	NULL
all	NULL
three	NULL
transcription	NULL
factors	NULL
contribute	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IL-2	NULL
,	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
NF-KB	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
an	NULL
important	NULL
factor	NULL
in	NULL
initiating	NULL
the	NULL
transcriptional	NULL
response	NULL
to	NULL
TCR	NULL
and	NULL
CD28	NULL
ligation	NULL
,	NULL
expression	NULL
of	NULL
IL-2	NULL
,	NULL
and	NULL
proliferation	NULL
(	NULL
24-27	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
pervasive	NULL
in	NULL
immune	NULL
tissues	NULL
and	NULL
plays	NULL
an	NULL
important	NULL
function	NULL
in	NULL
the	NULL
regulation	NULL
and	NULL
the	NULL
development	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
through	NULL
the	NULL
regulation	NULL
of	NULL
cytokines	NULL
and	NULL
cell	NULL
surface	NULL
markers	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

28-31	NULL
)	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B/Rel	NULL
protein	NULL
family	NULL
has	NULL
many	NULL
members	NULL
and	NULL
consists	NULL
of	NULL
DNA	NULL
binding	NULL
proteins	NULL
that	NULL
interact	NULL
to	NULL
form	NULL
dimers	NULL
with	NULL
one	NULL
another	NULL
through	NULL
a	NULL
region	NULL
termed	NULL
the	NULL
Rel	NULL
homology	NULL
domain	NULL
.	NULL

The	NULL
Rel	NULL
domain	NULL
is	NULL
a	NULL
highly	NULL
conserved	NULL
300-aa	NULL
region	NULL
that	NULL
mediates	NULL
protein-protein	NULL
interaction	NULL
and	NULL
DNA	NULL
binding	NULL
.	NULL

There	NULL
are	NULL
five	NULL
genes	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
in	NULL
humans	NULL
:	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
NF-	NULL
«	NULL
B2	NULL
(	NULL
p52	NULL
)	NULL
,	NULL
RelA	NULL
,	NULL
cRel	NULL
,	NULL
and	NULL
Rel	NULL
B	NULL
.	NULL

These	NULL
factors	NULL
mediate	NULL
nuclear	NULL
responses	NULL
to	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
inducers	NULL
,	NULL
such	NULL
as	NULL
cytokines	NULL
,	NULL
bacterial	NULL
products	NULL
,	NULL
viral	NULL
products	NULL
,	NULL
apoptotic	NULL
signals	NULL
,	NULL
and	NULL
other	NULL
forms	NULL
of	NULL
cellular	NULL
stress	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
can	NULL
be	NULL
identified	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
numerous	NULL
genes	NULL
that	NULL
are	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
ligation	NULL
,	NULL
including	NULL
IL-2	NULL
(	NULL
19	NULL
)	NULL
,	NULL
GM-CSF	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
,	NULL
IL-4	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
FasL	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
critical	NULL
role	NULL
of	NULL
NF-KB	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
IL-2	NULL
production	NULL
can	NULL
best	NULL
be	NULL
seen	NULL
in	NULL
transgenic	NULL
mice	NULL
that	NULL
have	NULL
homologous	NULL
deletion	NULL
of	NULL
genes	NULL
for	NULL
specific	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
.	NULL

These	NULL
mice	NULL
display	NULL
impaired	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
low	NULL
levels	NULL
of	NULL
IL-2	NULL
,	NULL
supporting	NULL
the	NULL
vital	NULL
function	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
in	NULL
T	NULL
cell	NULL
function	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
T	NULL
cell	NULL
effector	NULL
dysfunction	NULL
seen	NULL
in	NULL
SLE	NULL
can	NULL
be	NULL
a	NULL
direct	NULL
consequence	NULL
of	NULL
surface	NULL
membrane-initiated	NULL
signaling	NULL
abnor-malities	NULL
,	NULL
altered	NULL
nuclear	NULL
transcription	NULL
factor	NULL
expression	NULL
may	NULL
add	NULL
to	NULL
the	NULL
immunopathogenesis	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Because	NULL
IL-2	NULL
is	NULL
one	NULL
of	NULL
the	NULL
earliest	NULL
cytokines	NULL
expressed	NULL
after	NULL
TCR	NULL
ligation	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
factors	NULL
that	NULL
regulate	NULL
IL-2	NULL
production	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
understand	NULL
the	NULL
regulation	NULL
of	NULL
NF-KB	NULL
in	NULL
lupus	NULL
and	NULL
conducted	NULL
experiments	NULL
to	NULL
investigate	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
NF-KB	NULL
0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
pathway	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
SLE	NULL
T	NULL
cells	NULL
display	NULL
defective	NULL
inducible	NULL
forms	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Lymphocyte	NULL
isolation	NULL
Peripheral	NULL
blood	NULL
was	NULL
donated	NULL
by	NULL
volunteers	NULL
after	NULL
informed	NULL
consent	NULL
was	NULL
obtained	NULL
from	NULL
normal	NULL
and	NULL
diseased	NULL
individuals	NULL
according	NULL
to	NULL
protocols	NULL
approved	NULL
by	NULL
the	NULL
source	NULL
institutions	NULL
as	NULL
per	NULL
Walter	NULL
Reed	NULL
Army	NULL
Medical	NULL
Center	NULL
Human	NULL
Use	NULL
Committee	NULL
protocol	NULL
3727-98	NULL
.	NULL

PBMC	NULL
were	NULL
separated	NULL
from	NULL
RBC	NULL
on	NULL
Lymphoprep	NULL
gradient	NULL
(	NULL
Nycomed	NULL
Pharma	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
,	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
separated	NULL
subsequently	NULL
by	NULL
rosetting	NULL
with	NULL
neuraminadase-treated	NULL
SRBC	NULL
by	NULL
incubating	NULL
PBMC	NULL
and	NULL
SRBC	NULL
at	NULL
4°C	NULL
overnight	NULL
,	NULL
followed	NULL
by	NULL
further	NULL
separation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
centrifugation	NULL
on	NULL
Lymphoprep	NULL
gradient	NULL
.	NULL

Rosetted	NULL
T	NULL
cells	NULL
were	NULL
centrifuged	NULL
and	NULL
washed	NULL
with	NULL
PBS	NULL
.	NULL

SRBC	NULL
were	NULL
removed	NULL
by	NULL
incubating	NULL
for	NULL
5	NULL
min	NULL
in	NULL
ACK	NULL
lysing	NULL
buffer	NULL
(	NULL
0.15	NULL
M	NULL
NHgqCI	NULL
,	NULL
l	NULL
mM	NULL
KHCO	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
dilution	NULL
with	NULL
five	NULL
times	NULL
excess	NULL
RPMI	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
separated	NULL
by	NULL
centrifugation	NULL
at	NULL
1400	NULL
X	NULL
g	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
rested	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37°C	NULL
before	NULL
stimulation	NULL
.	NULL

The	NULL
purified	NULL
cells	NULL
are	NULL
>	NULL
95	NULL
%	NULL
positive	NULL
for	NULL
CD3	NULL
.	NULL

Immediately	NULL
before	NULL
stimulation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
fresh	NULL
RPMI	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
resuspended	NULL
in	NULL
a	NULL
1-ml	NULL
volume	NULL
with	NULL
the	NULL
appropriate	NULL
activating	NULL
agent	NULL
.	NULL

The	NULL
volume	NULL
was	NULL
brought	NULL
up	NULL
to	NULL
5	NULL
ml	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
the	NULL
remaining	NULL
time	NULL
after	NULL
stimulation	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
incubator	NULL
.	NULL

Antibodies	NULL
Abs	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
:	NULL
anti-p50	NULL
Ab	NULL
,	NULL
anti-p52	NULL
Ab	NULL
,	NULL
anti-c-Rel	NULL
Ab	NULL
,	NULL
anti-p65	NULL
(	NULL
RelA	NULL
)	NULL
N-terminal	NULL
Ab	NULL
,	NULL
anti-p65	NULL
(	NULL
RelA	NULL
)	NULL
C-terminal	NULL
Ab	NULL
,	NULL
and	NULL
anti-ReIB	NULL
Ab	NULL
.	NULL

Anti-CD3	NULL
(	NULL
OKT3	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Ortho	NULL
Biotech	NULL
(	NULL
Rantan	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
and	NULL
anti-CD28	NULL
Ab	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Protein	NULL
immunoblotting	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Harlow	NULL
and	NULL
Lane	NULL
(	NULL
33	NULL
)	NULL
.	NULL

A	NULL
total	NULL
of	NULL
15	NULL
pg	NULL
of	NULL
protein	NULL
extracts	NULL
was	NULL
denatured	NULL
at	NULL
95°C	NULL
in	NULL
2	NULL
%	NULL
laemmli	NULL
buffer	NULL
for	NULL
2	NULL
min	NULL
and	NULL
loaded	NULL
onto	NULL
10	NULL
%	NULL
Trig	NULL
glycine	NULL
SDS	NULL
gel	NULL
(	NULL
Novex	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
electrophoresed	NULL
at	NULL
125	NULL
V	NULL
constant	NULL
.	NULL

Protein	NULL
was	NULL
transferred	NULL
to	NULL
Immobilon	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
(	NULL
Milli-pore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
in	NULL
transfer	NULL
buffer	NULL
at	NULL
14	NULL
V	NULL
for	NULL
3	NULL
h.	NULL
The	NULL
membranes	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
and	NULL
blocked	NULL
with	NULL
PBS	NULL
+	NULL
3	NULL
%	NULL
dry	NULL
milk	NULL
for	NULL
1	NULL
h	NULL
and	NULL
incubated	NULL
in	NULL
primary	NULL
Ab	NULL
(	NULL
1:1000	NULL
dilution	NULL
)	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
membrane	NULL
was	NULL
then	NULL
washed	NULL
in	NULL
PBS	NULL
for	NULL
5	NULL
min	NULL
with	NULL
three	NULL
changes	NULL
of	NULL
buffer	NULL
,	NULL
reblocked	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
then	NULL
probed	NULL
with	NULL
secondary	NULL
Ab	NULL
at	NULL
1:1000	NULL
dilution	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
membrane	NULL
was	NULL
washed	NULL
in	NULL
PBS	NULL
+	NULL
0.05	NULL
%	NULL
Tween	NULL
six	NULL
times	NULL
for	NULL
5	NULL
min	NULL
each	NULL
,	NULL
and	NULL
the	NULL
bands	NULL
of	NULL
interest	NULL
were	NULL
visualized	NULL
by	NULL
chemiluminescence	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
.	NULL
)	NULL

.	NULL

Protein	NULL
isolation	NULL
At	NULL
least	NULL
10	NULL
million	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
preparation	NULL
of	NULL
extracts	NULL
for	NULL
each	NULL
experimental	NULL
point	NULL
.	NULL

T	NULL
cells	NULL
following	NULL
treatment	NULL
with	NULL
appropriate	NULL
stimulus	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
extracted	NULL
for	NULL
protein	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
in	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES-KOH	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
at	NULL
4°C	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
KCl	NULL
)	NULL
with	NULL
protease	NULL
inhibitor	NULL
mixture	NULL
(	NULL
1	NULL
uM	NULL
PMSF	NULL
,	NULL
1	NULL
gM	NULL
DTT	NULL
,	NULL
2	NULL
pg/pl	NULL
leupeptin	NULL
,	NULL
1	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
5	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
vanadate	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
200	NULL
pl	NULL
per	NULL
10	NULL
million	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
and	NULL
centrifuged	NULL
at	NULL
1000	NULL
X	NULL
g.	NULL
The	NULL
cell	NULL
pellets	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
buffer	NULL
B	NULL
(	NULL
20	NULL
mM	NULL
HEPES-KOH	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
with	NULL
protease	NULL
inhibitor	NULL
mixture	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
followed	NULL
by	NULL
brief	NULL
sonication	NULL
and	NULL
centrifugation	NULL
at	NULL
15,000	NULL
rpm	NULL
in	NULL
mi-crofuge	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
collected	NULL
and	NULL
the	NULL
protein	NULL
concentration	NULL
quantified	NULL
using	NULL
Bio-Rad	NULL
(	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
protein	NULL
assay	NULL
.	NULL

The	NULL
protein	NULL
extract	NULL
was	NULL
then	NULL
stored	NULL
at	NULL
-80°C	NULL
until	NULL
needed	NULL
for	NULL
EMSA	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

EMSA	NULL
Double-stranded	NULL
«	NULL
B	NULL
oligos	NULL
,	NULL
5'-gatcccaacggcaggggaattcecctctectta	NULL
and	NULL
the	NULL
complement	NULL
strand	NULL
,	NULL
were	NULL
custom	NULL
synthesized	NULL
from	NULL
Life	NULL
Technologies	NULL
(	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

The	NULL
«	NULL
B	NULL
oligonucleotides	NULL
were	NULL
end-labeled	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
ATP	NULL
(	NULL
NEN/DuPont	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
using	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Unincorporated	NULL
label	NULL
was	NULL
separated	NULL
using	NULL
Sephadex	NULL
G50	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
spin	NULL
col-umn	NULL
.	NULL

For	NULL
binding	NULL
reaction	NULL
,	NULL
15000	NULL
cpm	NULL
of	NULL
radiolabeled	NULL
xB	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
lymphocyte	NULL
protein	NULL
extract	NULL
in	NULL
binding	NULL
buffer	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
as	NULL
nonspecific	NULL
competitor	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
tem-	NULL
1683	NULL
perature	NULL
and	NULL
loaded	NULL
on	NULL
5	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
buffer	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
then	NULL
dried	NULL
under	NULL
vacuum	NULL
on	NULL
blotting	NULL
paper	NULL
and	NULL
the	NULL
protein	NULL
DNA	NULL
complexes	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Data	NULL
analysis	NULL
For	NULL
analysis	NULL
of	NULL
the	NULL
optical	NULL
density	NULL
of	NULL
the	NULL
band	NULL
for	NULL
NF-B	NULL
,	NULL
autoradiograms	NULL
were	NULL
scanned	NULL
with	NULL
a	NULL
Hewlett-Packard	NULL
(	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
scanner	NULL
and	NULL
analyzed	NULL
using	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Image	NULL
program	NULL
version	NULL
1.61	NULL
.	NULL

The	NULL
relative	NULL
optical	NULL
density	NULL
on	NULL
the	NULL
autoradiogram	NULL
was	NULL
recorded	NULL
,	NULL
and	NULL
statistically	NULL
significant	NULL
differences	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Mann-Whitney	NULL
U	NULL
test	NULL
and	NULL
the	NULL
Kruskal-Wallis	NULL
test	NULL
.	NULL

Statistical	NULL
significance	NULL
comparing	NULL
treated	NULL
patients	NULL
to	NULL
untreated	NULL
patients	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
one-way	NULL
ANOVA	NULL
.	NULL

Results	NULL
TCR-mediated	NULL
induction	NULL
of	NULL
NF-KB	NULL
is	NULL
defective	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
After	NULL
stimulation	NULL
through	NULL
the	NULL
TCR	NULL
using	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
mAbs	NULL
,	NULL
efficient	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
can	NULL
be	NULL
readily	NULL
detected	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
by	NULL
EMSA	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Stimulation	NULL
solely	NULL
through	NULL
the	NULL
TCR	NULL
by	NULL
anti-CD3	NULL
mAb	NULL
did	NULL
not	NULL
effectively	NULL
activate	NULL
NF-KB	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

14	NULL
.	NULL

The	NULL
development	NULL
of	NULL
doublet	NULL
bands	NULL
,	NULL
which	NULL
disappear	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
unlabeled	NULL
«	NULL
B	NULL
oligonucleotide	NULL
,	NULL
demonstrate	NULL
the	NULL
specificity	NULL
of	NULL
DNA	NULL
binding	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Time	NULL
course	NULL
experiments	NULL
determined	NULL
the	NULL
optimal	NULL
time	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
to	NULL
be	NULL
6	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

Although	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
activated	NULL
after	NULL
3	NULL
h	NULL
(	NULL
5-fold	NULL
)	NULL
,	NULL
greater	NULL
levels	NULL
of	NULL
DNA	NULL
binding	NULL
were	NULL
consistently	NULL
detected	NULL
at	NULL
6	NULL
h	NULL
(	NULL
5.5-	NULL
to	NULL
7-fold	NULL
)	NULL
.	NULL

This	NULL
activation	NULL
of	NULL
the	NULL
NF-KB	NULL
is	NULL
best	NULL
followed	NULL
by	NULL
the	NULL
slower	NULL
migrating	NULL
upper	NULL
band	NULL
,	NULL
which	NULL
disappears	NULL
when	NULL
competed	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
«	NULL
B-specific	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Protein	NULL
extracts	NULL
from	NULL
freshly	NULL
isolated	NULL
T	NULL
cells	NULL
from	NULL
SLE	NULL
patients	NULL
were	NULL
analyzed	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
following	NULL
stimulation	NULL
with	NULL
anti-CD3/anti-CD28	NULL
mAbs	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
EMSA	NULL
in	NULL
nine	NULL
SLE	NULL
patients	NULL
,	NULL
displayed	NULL
both	NULL
qualitative	NULL
and	NULL
quantitative	NULL
differences	NULL
when	NULL
compared	NULL
with	NULL
that	NULL
seen	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
intensity	NULL
,	NULL
when	NULL
measured	NULL
by	NULL
densi-tometry	NULL
,	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
was	NULL
>	NULL
2	NULL
SD	NULL
below	NULL
the	NULL
normal	NULL
mean	NULL
in	NULL
five	NULL
patients	NULL
(	NULL
SLE4	NULL
,	NULL
SLE18	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
D	NULL
)	NULL
,	NULL
decreased	NULL
,	NULL
as	NULL
defined	NULL
by	NULL
an	NULL
intensity	NULL
between	NULL
1	NULL
and	NULL
2	NULL
SD	NULL
below	NULL
the	NULL
normal	NULL
mean	NULL
,	NULL
in	NULL
four	NULL
patients	NULL
(	NULL
SLE6	NULL
and	NULL
SLE19	NULL
in	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
band	NULL
,	NULL
which	NULL
is	NULL
also	NULL
specific	NULL
for	NULL
NF-kB	NULL
binding	NULL
,	NULL
was	NULL
similar	NULL
in	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
T	NULL
cells	NULL
in	NULL
both	NULL
normal	NULL
and	NULL
SLE	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
observed	NULL
decreased	NULL
NF-KB	NULL
binding	NULL
activity	NULL
was	NULL
limited	NULL
to	NULL
SLE	NULL
patients	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
eight	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
RA	NULL
)	NULL
were	NULL
analyzed	NULL
.	NULL

All	NULL
protein	NULL
extracts	NULL
from	NULL
RA	NULL
T	NULL
cells	NULL
showed	NULL
detectable	NULL
upper	NULL
bands	NULL
for	NULL
NF-KB	NULL
,	NULL
albeit	NULL
of	NULL
less	NULL
intensity	NULL
than	NULL
normal	NULL
T	NULL
cells	NULL
in	NULL
certain	NULL
RA	NULL
patients	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
a	NULL
low-grade	NULL
T	NULL
cell	NULL
malignancy	NULL
(	NULL
cutaneous	NULL
T	NULL
cell	NULL
lymphoma	NULL
)	NULL
did	NULL
not	NULL
show	NULL
abnormal	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NF-KB	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
A23187	NULL
It	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
certain	NULL
TCR-mediated	NULL
signaling	NULL
events	NULL
,	NULL
such	NULL
as	NULL
increases	NULL
in	NULL
intracytoplasmic	NULL
calcium	NULL
(	NULL
3	NULL
)	NULL
and	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
4	NULL
)	NULL
,	NULL
are	NULL
abnormal	NULL
in	NULL
lupus	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
novel	NULL
abnormality	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
SLE	NULL
patients	NULL
was	NULL
the	NULL
result	NULL
of	NULL
defective	NULL
initiation	NULL
of	NULL
signaling	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
through	NULL
the	NULL
Ag	NULL
receptor	NULL
and	NULL
CD28	NULL
receptors	NULL
,	NULL
PMA	NULL
and	NULL
the	NULL
calcium	NULL
ionophore	NULL
,	NULL
A23187	NULL
,	NULL
which	NULL
activate	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
intracellular	NULL
second	NULL
messenger	NULL
pathways	NULL
,	NULL
were	NULL
used	NULL
to	NULL
assess	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

SLE	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA/A23187	NULL
,	NULL
protein	NULL
extracts	NULL
were	NULL
isolated	NULL
at	NULL
6	NULL
h	NULL
,	NULL
and	NULL
the	NULL
extracts	NULL
were	NULL
analyzed	NULL
for	NULL
kB	NULL
binding	NULL
activity	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
a	NULL
defect	NULL
in	NULL
NF-KB	NULL
activation	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
1684	NULL
A	NULL
)	NULL
aCD3/	NULL
Unstim	NULL
_	NULL
aCD28	NULL
aCD3	NULL
-	NULL
+	NULL
comp	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
~-3z	NULL
8	NULL
8	NULL
u	NULL
Free	NULL
probe®	NULL
0	NULL
3	NULL
6	NULL
6	NULL
Time	NULL
(	NULL
Hr	NULL
)	NULL
C	NULL
)	NULL
Normal	NULL
_	NULL
SLE4	NULL
-	NULL
SLE18	NULL
-	NULL
SLE19	NULL
SLE6	NULL
aCD3laCD28	NULL
-	NULL
-	NULL
-	NULL
+	NULL
+	NULL
[	NULL
|-	NULL
-	NULL
++|-	NULL
=	NULL
mp	NULL
-|+-	NULL
+	NULL
+|	NULL
--	NULL
++	NULL
Competitor	NULL
=	NULL
-	NULL
4+	NULL
-	NULL
+11	NULL
$	NULL
L	NULL
411	NULL
¢	NULL
~	NULL
#	NULL
!	NULL

.	NULL

$	NULL
4	NULL
-	NULL
41	NULL
>	NULL
+	NULL
-+	NULL
NFK	NULL
‘	NULL
B	NULL
:	NULL
had	NULL
'	NULL
ws	NULL
is	NULL
d	NULL
m	NULL
NF-	NULL
«	NULL
B	NULL
ABNORMALITIES	NULL
IN	NULL
HUMAN	NULL
SLE	NULL
B	NULL
)	NULL
L	NULL
aCD3/	NULL
aCD3	NULL
aCD28	NULL
Relative	NULL
abs	NULL
0	NULL
3	NULL
6	NULL
6	NULL
Time	NULL
(	NULL
Hr	NULL
)	NULL
D	NULL
)	NULL
Normal	NULL
RA1	NULL
SLE4	NULL
«	NULL
CD3/aCD28	NULL
1040	NULL
4	NULL
Ao	NULL
.	NULL

.	NULL

$	NULL
A	NULL
.	NULL

.	NULL

+o	NULL
Competition	NULL
80	NULL
%	NULL
0	NULL
.	NULL

¢	NULL
2	NULL
$	NULL
020	NULL
$	NULL
2	NULL
g	NULL
c	NULL
o	NULL
%	NULL
F	NULL
rec	NULL
~	NULL
»	NULL
>	NULL
Soth	NULL
<	NULL
n	NULL
»	NULL
aan	NULL
ana	NULL
dae	NULL
tau	NULL
ta	NULL
tad	NULL
ta	NULL
ta	NULL
ta	NULL
tan	NULL
s	NULL
t	NULL
p65	NULL
Relative	NULL
Abs	NULL
FIGURE	NULL
1	NULL
.	NULL

Free	NULL
age	NULL
cn	NULL
ligh	NULL
<	NULL
>	NULL
dh	NULL
Ce	NULL
tua	NULL
cme	NULL
Oi	NULL
res	NULL
As	NULL
ames	NULL
Ot	NULL
Anti-CD3	NULL
and	NULL
anti-CD28	NULL
mAb-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

A	NULL
,	NULL
Activation	NULL
of	NULL
NF-B	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3/anti-CD28	NULL
mAb	NULL
or	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
for	NULL
the	NULL
time	NULL
indicated	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
from	NULL
T	NULL
cells	NULL
at	NULL
the	NULL
time	NULL
indicated	NULL
after	NULL
activation	NULL
,	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
analyzed	NULL
in	NULL
EMSA	NULL
.	NULL

Arrows	NULL
indicate	NULL
specific	NULL
bands	NULL
that	NULL
bound	NULL
to	NULL
the	NULL
«	NULL
B	NULL
oligonucleotide	NULL
.	NULL

Competition	NULL
with	NULL
100	NULL
%	NULL
excess	NULL
of	NULL
unlabeled	NULL
«	NULL
B	NULL
oligonucleotide	NULL
shows	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
NF-KB	NULL
interaction	NULL
.	NULL

B	NULL
,	NULL
The	NULL
optical	NULL
density	NULL
of	NULL
the	NULL
induced	NULL
upper	NULL
band	NULL
of	NULL
A	NULL
was	NULL
scanned	NULL
and	NULL
plotted	NULL
on	NULL
bar	NULL
graph	NULL
.	NULL

C	NULL
,	NULL
SLE	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3/anti-CD28	NULL
mAb	NULL
for	NULL
6	NULL
h	NULL
and	NULL
nuclear	NULL
extracts	NULL
purified	NULL
.	NULL

A	NULL
total	NULL
of	NULL
1	NULL
pg	NULL
of	NULL
extracts	NULL
was	NULL
analyzed	NULL
in	NULL
EMSA	NULL
using	NULL
kB	NULL
probe	NULL
,	NULL
and	NULL
bands	NULL
specific	NULL
for	NULL
NF-KB	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
arrows	NULL
.	NULL

D	NULL
,	NULL
NF-KB	NULL
activity	NULL
in	NULL
lymphocyte	NULL
extracts	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
RA	NULL
are	NULL
shown	NULL
in	NULL
comparison	NULL
with	NULL
those	NULL
from	NULL
a	NULL
normal	NULL
individual	NULL
and	NULL
an	NULL
SLE	NULL
patient	NULL
.	NULL

was	NULL
seen	NULL
when	NULL
compared	NULL
with	NULL
normals	NULL
.	NULL

Out	NULL
of	NULL
18	NULL
patients	NULL
ana-lyzed	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
was	NULL
>	NULL
2	NULL
SD	NULL
below	NULL
the	NULL
normal	NULL
mean	NULL
in	NULL
nine	NULL
patients	NULL
,	NULL
between	NULL
1	NULL
and	NULL
2	NULL
SD	NULL
below	NULL
the	NULL
normal	NULL
mean	NULL
in	NULL
seven	NULL
patients	NULL
,	NULL
and	NULL
within	NULL
1	NULL
SD	NULL
of	NULL
the	NULL
normal	NULL
mean	NULL
in	NULL
two	NULL
patients	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
a	NULL
defect	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
resided	NULL
downstream	NULL
from	NULL
the	NULL
surface	NULL
signaling	NULL
machinery	NULL
.	NULL

In	NULL
certain	NULL
lupus	NULL
individuals	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
by	NULL
both	NULL
methods	NULL
,	NULL
either	NULL
with	NULL
anti-CD3/anti-CD28	NULL
mAbs	NULL
or	NULL
PMA/A23187	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
when	NULL
stimulated	NULL
by	NULL
these	NULL
two	NULL
methods	NULL
were	NULL
always	NULL
found	NULL
to	NULL
be	NULL
concordant	NULL
in	NULL
an	NULL
SLE	NULL
patient	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

Defective	NULL
NF-KB	NULL
activation	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
is	NULL
not	NULL
the	NULL
result	NULL
of	NULL
abnormal	NULL
kinetics	NULL
of	NULL
activation	NULL
We	NULL
considered	NULL
the	NULL
possibility	NULL
that	NULL
abnormal	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
may	NULL
reflect	NULL
aberrant	NULL
kinetics	NULL
of	NULL
NF-KB	NULL
activation	NULL
.	NULL

The	NULL
anti-CD3	NULL
mAb-mediated	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
lupus	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
reach	NULL
peak	NULL
levels	NULL
earlier	NULL
than	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
SLE	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
displayed	NULL
abnormal	NULL
activation	NULL
when	NULL
stimulated	NULL
with	NULL
PMA/	NULL
A23187	NULL
or	NULL
anti-CD3/anti-CD28	NULL
mAbs	NULL
,	NULL
showed	NULL
abnormal	NULL
kinetics	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
shows	NULL
the	NULL
NF-KB	NULL
binding	NULL
activity	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
at	NULL
times	NULL
0	NULL
,	NULL
3	NULL
,	NULL
and	NULL
6	NULL
h	NULL
after	NULL
initiation	NULL
of	NULL
stimulation	NULL
.	NULL

The	NULL
kB	NULL
binding	NULL
activity	NULL
remained	NULL
absent	NULL
throughout	NULL
the	NULL
time	NULL
pe	NULL
riod	NULL
analyzed	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
level	NULL
of	NULL
NF-KB	NULL
seen	NULL
in	NULL
normal	NULL
lymphocyte	NULL
extracts	NULL
was	NULL
rapidly	NULL
induced	NULL
and	NULL
remained	NULL
stable	NULL
over	NULL
the	NULL
time	NULL
course	NULL
that	NULL
was	NULL
studied	NULL
.	NULL

p65	NULL
,	NULL
but	NULL
not	NULL
p50	NULL
,	NULL
activity	NULL
is	NULL
abnormal	NULL
in	NULL
lupus	NULL
T	NULL
cells	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
composed	NULL
of	NULL
five	NULL
genetically	NULL
distinct	NULL
family	NULL
members	NULL
that	NULL
,	NULL
through	NULL
protein-protein	NULL
interactions	NULL
,	NULL
form	NULL
homo-	NULL
or	NULL
heterodimers	NULL
that	NULL
constitute	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
35	NULL
)	NULL
.	NULL

To	NULL
define	NULL
the	NULL
NF-KB	NULL
abnormality	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
added	NULL
Abs	NULL
specific	NULL
to	NULL
various	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
in	NULL
the	NULL
EMSA	NULL
binding	NULL
reaction	NULL
with	NULL
SLE	NULL
extracts	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
only	NULL
the	NULL
p50	NULL
subunit	NULL
is	NULL
detected	NULL
by	NULL
DNA	NULL
binding	NULL
assays	NULL
in	NULL
extracts	NULL
isolated	NULL
from	NULL
unstimulated	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
other	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
members	NULL
are	NULL
not	NULL
detected	NULL
as	NULL
part	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

When	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
,	NULL
p50	NULL
homodimer	NULL
,	NULL
p65	NULL
(	NULL
ReIA	NULL
)	NULL
-p50	NULL
heterodimer	NULL
and	NULL
p65	NULL
(	NULL
ReIA	NULL
)	NULL
homodimer	NULL
complexes	NULL
formed	NULL
,	NULL
which	NULL
appeared	NULL
as	NULL
doublet	NULL
bands	NULL
.	NULL

The	NULL
p50	NULL
homodimers	NULL
constitute	NULL
the	NULL
faster	NULL
migrating	NULL
band	NULL
,	NULL
and	NULL
the	NULL
slower	NULL
,	NULL
upper	NULL
band	NULL
is	NULL
composed	NULL
of	NULL
p50-p65	NULL
heterodimers	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
or	NULL
p65	NULL
homodimers	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
specific	NULL
Abs	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

Anti-p50	NULL
Ab	NULL
disrupted	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
lower	NULL
band	NULL
and	NULL
led	NULL
to	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
new	NULL
slower	NULL
migrating	NULL
band	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
shifted	NULL
larger	NULL
complex	NULL
.	NULL

Anti-p65	NULL
Ab	NULL
specifically	NULL
eliminates	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
because	NULL
the	NULL
Ab	NULL
that	NULL
binds	NULL
this	NULL
subunit	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
)	NULL
E0	NULL
g	NULL
3	NULL
%	NULL
;	NULL
20	NULL
9	NULL
§§	NULL
|	NULL
5	NULL
Ss	NULL
§§	NULL
&	NULL
44	NULL
1685	NULL
B	NULL
)	NULL
Normal	NULL
SLE9	NULL
Normal	NULL
SLE12	NULL
SLE11	NULL
PMA/AZM87	NULL
|	NULL
~	NULL
=	NULL
0	NULL
+	NULL
O+	NULL
o-	NULL
-~	NULL
0	NULL
t	NULL
O+	NULL
PMA/	NULL
comp	NULL
-	NULL
-	NULL
-o	NULL
+00	NULL
-	NULL
#	NULL
0	NULL
to	NULL
*	NULL
-o	NULL
*	NULL
_	NULL
A2ZM187	NULL
co	NULL
+o	NULL
ot	NULL
ot	NULL
c	NULL
o*	NULL
t	NULL
\i	NULL
W	NULL
-	NULL
»	NULL
e	NULL
l	NULL
``	NULL
'	NULL
~	NULL
-	NULL
Clad	NULL
a	NULL
“	NULL
C	NULL
Normal	NULL
RA	NULL
SLE	NULL
PMA/Ca++	NULL
=	NULL
.	NULL

+00	NULL
-	NULL
-	NULL
+	NULL
-	NULL
100	NULL
+	NULL
«	NULL
CD3	NULL
1	NULL
1	NULL
+	NULL
l	NULL
-	NULL
po	NULL
.-	NULL
-	NULL
+	NULL
«	NULL
CD28	NULL
»	NULL
an	NULL
“	NULL
Soul	NULL
Aah	NULL
Aal	NULL
t	NULL
al	NULL
t	NULL
ah	NULL
s	NULL
1	NULL
tiled	NULL
.	NULL

Alit	NULL
FIGURE	NULL
2	NULL
.	NULL

-	NULL
Stimulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
lymphocyte	NULL
with	NULL
PMA/A23187	NULL
.	NULL

A	NULL
,	NULL
Comparable	NULL
levels	NULL
of	NULL
NF-KB	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
stimulation	NULL
with	NULL
either	NULL
anti-CD3/anti-CD28	NULL
mAbs	NULL
or	NULL
PMA/A23187	NULL
in	NULL
normal	NULL
lymphocytes	NULL
.	NULL

Cells	NULL
were	NULL
induced	NULL
with	NULL
the	NULL
designated	NULL
agents	NULL
for	NULL
6	NULL
h	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
by	NULL
incubating	NULL
1	NULL
pg	NULL
of	NULL
nuclear	NULL
extracts	NULL
with	NULL
«	NULL
B-labeled	NULL
probe	NULL
.	NULL

The	NULL
specific	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
nondenaturing	NULL
0.5	NULL
%	NULL
TBE	NULL
PAGE	NULL
.	NULL

B	NULL
,	NULL
Extracts	NULL
from	NULL
SLE	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA/A23187	NULL
for	NULL
6	NULL
h	NULL
were	NULL
analyzed	NULL
for	NULL
xB	NULL
binding	NULL
activity	NULL
in	NULL
EMSA	NULL
.	NULL

EMSA	NULL
experiment	NULL
from	NULL
normal	NULL
T	NULL
cells	NULL
is	NULL
shown	NULL
for	NULL
comparison	NULL
.	NULL

C	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
stimulated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
either	NULL
antiCD3/anti-CD28	NULL
mAb	NULL
or	NULL
PMA/A23187	NULL
.	NULL

Both	NULL
methods	NULL
of	NULL
stimulating	NULL
T	NULL
cells	NULL
yielded	NULL
similar	NULL
levels	NULL
of	NULL
NF-KB	NULL
activation	NULL
as	NULL
measured	NULL
by	NULL
EMSA	NULL
.	NULL

is	NULL
incompatible	NULL
with	NULL
DNA	NULL
binding	NULL
in	NULL
EMSA	NULL
.	NULL

Other	NULL
members	NULL
that	NULL
constitute	NULL
NF-KB	NULL
activity	NULL
,	NULL
such	NULL
as	NULL
p52	NULL
and	NULL
RelB	NULL
,	NULL
are	NULL
predominantly	NULL
expressed	NULL
in	NULL
accessory	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
dendritic	NULL
cells	NULL
and	NULL
macrophages	NULL
,	NULL
and	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
these	NULL
proteins	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
normal	NULL
T	NULL
cells	NULL
using	NULL
subunit-specific	NULL
Abs	NULL
.	NULL

FIGURE	NULL
3	NULL
.	NULL

Comparison	NULL
-	NULL
of	NULL
the	NULL
kinetics	NULL
for	NULL
NF-KB	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
and	NULL
SLE	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
Equal	NULL
amounts	NULL
of	NULL
lymphocyte	NULL
extracts	NULL
,	NULL
1	NULL
pg	NULL
,	NULL
from	NULL
a	NULL
normal	NULL
and	NULL
SLE	NULL
patient	NULL
,	NULL
isolated	NULL
at	NULL
3	NULL
and	NULL
6	NULL
h	NULL
after	NULL
stimulation	NULL
,	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
.	NULL

B	NULL
,	NULL
Graph	NULL
of	NULL
relative	NULL
absorbance	NULL
of	NULL
the	NULL
band	NULL
corresponding	NULL
to	NULL
p65	NULL
is	NULL
shown	NULL
to	NULL
contrast	NULL
the	NULL
difference	NULL
in	NULL
activation	NULL
of	NULL
NF-KB	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
a	NULL
particular	NULL
NF-	NULL
«	NULL
B	NULL
subunit	NULL
was	NULL
abnormally	NULL
regulated	NULL
in	NULL
SLE	NULL
,	NULL
specific	NULL
Abs	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
were	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
in	NULL
EMSA	NULL
.	NULL

Similar	NULL
to	NULL
unstimulated	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
,	NULL
the	NULL
p50	NULL
component	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
supershifted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-p50	NULL
Ab	NULL
.	NULL

However	NULL
,	NULL
compared	NULL
with	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
a	NULL
profound	NULL
lack	NULL
of	NULL
the	NULL
p65	NULL
DNA	NULL
binding	NULL
A	NULL
)	NULL
B	NULL
)	NULL
SLE	NULL
14	NULL
160	NULL
140	NULL
;	NULL
-A	NULL
6	NULL
120	NULL
-~	NULL
Normal	NULL
3	NULL
6	NULL
0	NULL
3	NULL
Time	NULL
(	NULL
hrs	NULL
)	NULL
9	NULL
100	NULL
&	NULL
``	NULL
*	NULL
~*~	NULL
Norm	NULL
a	NULL
~	NULL
}	NULL
I	NULL
“	NULL
bee	NULL
60	NULL
-	NULL
``	NULL
SLE	NULL
40	NULL
/	NULL
Abs	NULL
\	NULL
20	NULL
1	NULL
|/	NULL
Time	NULL
(	NULL
Hrs	NULL
)	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
1686	NULL
FIGURE	NULL
4	NULL
.	NULL

Determination	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
present	NULL
in	NULL
DNA	NULL
binding	NULL
complexes	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
A	NULL
)	NULL
normal	NULL
individuals	NULL
and	NULL
SLE	NULL
patients	NULL
.	NULL

A	NULL
,	NULL
Equal	NULL
amounts	NULL
of	NULL
extracts	NULL
from	NULL
unstimulated	NULL
and	NULL
stimu-	NULL
lated	NULL
(	NULL
anti-CD3/anti-CD28	NULL
)	NULL
normal	NULL
T	NULL
cells	NULL
were	NULL
in	NULL
cubated	NULL
with	NULL
specified	NULL
Ab	NULL
(	NULL
0.5	NULL
ug	NULL
)	NULL
as	NULL
described	NULL
,	NULL
ex	NULL
cept	NULL
for	NULL
the	NULL
second	NULL
lane	NULL
where	NULL
100X	NULL
excess	NULL
unlabeled	NULL
kB	NULL
oligonucleotide	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reac-	NULL
tion	NULL
.	NULL

Supershifted	NULL
band	NULL
(	NULL
1	NULL
)	NULL
is	NULL
present	NULL
when	NULL
anti-p50	NULL
Ab	NULL
was	NULL
added	NULL
to	NULL
the	NULL
EMSA	NULL
reaction	NULL
.	NULL

Reduction	NULL
of	NULL
faster	NULL
migrating	NULL
band	NULL
(	NULL
3	NULL
)	NULL
is	NULL
seen	NULL
concomitantly	NULL
.	NULL

An	NULL
ti-p65	NULL
disrupts	NULL
the	NULL
middle	NULL
band	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Other	NULL
Abs	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
pattern	NULL
.	NULL

B	NULL
,	NULL
Extracts	NULL
from	NULL
stimulated	NULL
and	NULL
B	NULL
)	NULL
unstimulated	NULL
(	NULL
anti-CD3/anti-CD28	NULL
)	NULL
T	NULL
cells	NULL
from	NULL
SLE	NULL
patient	NULL
that	NULL
lack	NULL
the	NULL
slower	NULL
migrating	NULL
kB	NULL
band	NULL
.	NULL

Specific	NULL
Abs	NULL
(	NULL
0.5	NULL
ug	NULL
)	NULL
were	NULL
added	NULL
as	NULL
indicated	NULL
.	NULL

Only	NULL
the	NULL
anti-p50	NULL
Abs	NULL
disrupted	NULL
the	NULL
binding	NULL
pattern	NULL
in	NULL
both	NULL
unstimulated	NULL
and	NULL
stimulated	NULL
T	NULL
cells	NULL
by	NULL
the	NULL
appearance	NULL
of	NULL
band	NULL
1	NULL
and	NULL
decrease	NULL
in	NULL
band	NULL
3	NULL
.	NULL

Normal	NULL
SLE4	NULL
activity	NULL
was	NULL
found	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
when	NULL
analyzed	NULL
with	NULL
anti-p65	NULL
Ab	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
Abs	NULL
specific	NULL
for	NULL
the	NULL
other	NULL
NF-	NULL
«	NULL
B	NULL
members	NULL
failed	NULL
to	NULL
alter	NULL
the	NULL
NF-KB	NULL
binding	NULL
pattern	NULL
in	NULL
lupus	NULL
cells	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
their	NULL
absence	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
normal	NULL
and	NULL
lupus	NULL
cells	NULL
.	NULL

Defect	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
is	NULL
due	NULL
to	NULL
decreased	NULL
p65	NULL
protein	NULL
The	NULL
lack	NULL
of	NULL
p65	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
EMSA	NULL
assays	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
could	NULL
reflect	NULL
modifications	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
that	NULL
affect	NULL
its	NULL
ability	NULL
to	NULL
dimerize	NULL
with	NULL
other	NULL
family	NULL
members	NULL
and	NULL
bind	NULL
DNA	NULL
.	NULL

Alternatively	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
p65	NULL
protein	NULL
may	NULL
exist	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
and	NULL
is	NULL
either	NULL
unable	NULL
to	NULL
bind	NULL
DNA	NULL
or	NULL
is	NULL
inhibited	NULL
by	NULL
a	NULL
repressor	NULL
.	NULL

To	NULL
distinguish	NULL
among	NULL
these	NULL
possibilities	NULL
,	NULL
immunoblotting	NULL
of	NULL
whole	NULL
lymphocyte	NULL
proteins	NULL
transferred	NULL
to	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
was	NULL
performed	NULL
using	NULL
Abs	NULL
specific	NULL
to	NULL
p50	NULL
and	NULL
p65	NULL
.	NULL

Fig	NULL
.	NULL

5A	NULL
demonstrates	NULL
that	NULL
the	NULL
level	NULL
of	NULL
p50	NULL
in	NULL
extracts	NULL
from	NULL
SLE	NULL
T	NULL
cells	NULL
did	NULL
not	NULL
vary	NULL
from	NULL
one	NULL
patient	NULL
to	NULL
another	NULL
and	NULL
was	NULL
quantitatively	NULL
comparable	NULL
to	NULL
extracts	NULL
from	NULL
normal	NULL
and	NULL
RA	NULL
controls	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
level	NULL
of	NULL
p50	NULL
in	NULL
each	NULL
individual	NULL
did	NULL
not	NULL
change	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD3/anti-CD28	NULL
mAbs	NULL
or	NULL
PMA/A23187	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
amounts	NULL
of	NULL
p65	NULL
subunit	NULL
by	NULL
immuno-blotting	NULL
.	NULL

We	NULL
found	NULL
that	NULL
this	NULL
subunit	NULL
was	NULL
absent	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
SLE	NULL
patients	NULL
with	NULL
undetectable	NULL
p65	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
SLE4	NULL
and	NULL
SLE19	NULL
,	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
p65	NULL
levels	NULL
were	NULL
markedly	NULL
decreased	NULL
in	NULL
SLE	NULL
individuals	NULL
(	NULL
SLE12	NULL
and	NULL
SLE14	NULL
)	NULL
with	NULL
decreased	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
p65	NULL
band	NULL
in	NULL
RA	NULL
patients	NULL
was	NULL
quantitatively	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
normal	NULL
controls	NULL
.	NULL

Using	NULL
protein	NULL
extracts	NULL
from	NULL
the	NULL
same	NULL
patients	NULL
and	NULL
controls	NULL
,	NULL
we	NULL
reassessed	NULL
the	NULL
levels	NULL
of	NULL
p65	NULL
with	NULL
another	NULL
anti-p65	NULL
Ab	NULL
that	NULL
recognizes	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

We	NULL
again	NULL
noted	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
p65	NULL
protein	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
that	NULL
lack	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
there	NULL
is	NULL
an	NULL
abnormality	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
in	NULL
SLE	NULL
patients	NULL
and	NULL
that	NULL
it	NULL
is	NULL
associated	NULL
with	NULL
decreased/absent	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
p65	NULL
protein	NULL
was	NULL
detected	NULL
in	NULL
lysates	NULL
from	NULL
PBMC	NULL
from	NULL
SLE	NULL
patients	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
defect	NULL
was	NULL
limited	NULL
to	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
SLE	NULL
patients	NULL
remain	NULL
stable	NULL
over	NULL
time	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
lack	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
lupus	NULL
patients	NULL
is	NULL
a	NULL
transient	NULL
abnormality	NULL
or	NULL
is	NULL
stable	NULL
property	NULL
,	NULL
protein	NULL
extracts	NULL
2—	NULL
3	NULL
-	NULL
qu	NULL
“	NULL
Buuﬁl	NULL
NF-	NULL
«	NULL
B	NULL
ABNORMALITIES	NULL
IN	NULL
HUMAN	NULL
SLE	NULL
Unstimulated	NULL
Stimulated	NULL
a	NULL
wo	NULL
s	NULL
%	NULL
©	NULL
o	NULL
c	NULL
%	NULL
a	NULL
o	NULL
f	NULL
8	NULL
§	NULL
%	NULL
&	NULL
5	NULL
a	NULL
R	NULL
8	NULL
§	NULL
$	NULL
2	NULL
5	NULL
ee	NULL
wn	NULL
gong	NULL
mom	NULL
game	NULL
:	NULL
mmm	NULL
yom	NULL
:	NULL
rm	NULL
mmm	NULL
C1	NULL
C	NULL
£	NULL
Milk	NULL
§	NULL
%	NULL
idd	NULL
41.8	NULL
;	NULL
E	NULL
oaowmﬁ	NULL
‘	NULL
l	NULL
’	NULL
(	NULL
9°	NULL
a-	NULL
m-	NULL
%	NULL
o	NULL
g	NULL
$	NULL
%	NULL
b	NULL
€	NULL
$	NULL
9	NULL
se	NULL
$	NULL
b	NULL
b	NULL
Gb	NULL
$	NULL
g	NULL
g	NULL
:	NULL
®	NULL
°-..	NULL
,	NULL
,	NULL
'-	NULL
nv-l.	NULL
--	NULL
-	NULL
W	NULL
bo	NULL
bibb	NULL
from	NULL
the	NULL
same	NULL
individuals	NULL
were	NULL
obtained	NULL
at	NULL
different	NULL
times	NULL
,	NULL
and	NULL
the	NULL
p50/p65	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
was	NULL
quantified	NULL
.	NULL

The	NULL
time	NULL
intervals	NULL
between	NULL
the	NULL
initial	NULL
and	NULL
subsequent	NULL
analysis	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
each	NULL
SLE	NULL
patient	NULL
varied	NULL
from	NULL
1	NULL
to	NULL
15	NULL
mo	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
remained	NULL
stable	NULL
over	NULL
time	NULL
and	NULL
never	NULL
approached	NULL
the	NULL
level	NULL
exhibited	NULL
by	NULL
normal	NULL
individuals	NULL
.	NULL

The	NULL
level	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
over	NULL
time	NULL
remained	NULL
significantly	NULL
lower	NULL
than	NULL
the	NULL
average	NULL
of	NULL
the	NULL
level	NULL
of	NULL
normals	NULL
(	NULL
p	NULL
<	NULL
0.005	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Distribution	NULL
of	NULL
decreased	NULL
level	NULL
of	NULL
p65	NULL
activity	NULL
in	NULL
SLE	NULL
To	NULL
assess	NULL
the	NULL
relative	NULL
defect	NULL
in	NULL
the	NULL
level	NULL
of	NULL
NF-B	NULL
in	NULL
the	NULL
group	NULL
of	NULL
SLE	NULL
patients	NULL
tested	NULL
in	NULL
comparison	NULL
to	NULL
normal	NULL
volunteers	NULL
and	NULL
RA	NULL
patients	NULL
and	NULL
to	NULL
eliminate	NULL
interexperimental	NULL
variation	NULL
,	NULL
all	NULL
extract	NULL
samples	NULL
were	NULL
assayed	NULL
simultaneously	NULL
under	NULL
identical	NULL
EMSA	NULL
conditions	NULL
using	NULL
labeled	NULL
«	NULL
B	NULL
probes	NULL
.	NULL

The	NULL
level	NULL
of	NULL
p65	NULL
induction	NULL
was	NULL
scanned	NULL
from	NULL
the	NULL
autoradiographic	NULL
films	NULL
that	NULL
were	NULL
subjected	NULL
to	NULL
the	NULL
same	NULL
length	NULL
of	NULL
exposure	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
shows	NULL
the	NULL
relative	NULL
distribution	NULL
of	NULL
the	NULL
level	NULL
of	NULL
p65	NULL
from	NULL
individuals	NULL
after	NULL
either	NULL
stimulation	NULL
using	NULL
surface	NULL
stimulation	NULL
with	NULL
antiCD3¥/antiCD28	NULL
mAbs	NULL
or	NULL
PMA/	NULL
A23187	NULL
.	NULL

The	NULL
distribution	NULL
clearly	NULL
shows	NULL
that	NULL
normal	NULL
controls	NULL
always	NULL
show	NULL
inducible	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
that	NULL
falls	NULL
into	NULL
a	NULL
distinguishable	NULL
level	NULL
from	NULL
that	NULL
seen	NULL
for	NULL
the	NULL
SLE	NULL
group	NULL
.	NULL

The	NULL
SLE	NULL
group	NULL
showed	NULL
a	NULL
level	NULL
that	NULL
extends	NULL
from	NULL
undetectable	NULL
to	NULL
normal	NULL
.	NULL

The	NULL
mean	NULL
level	NULL
of	NULL
activity	NULL
in	NULL
SLE	NULL
patients	NULL
was	NULL
statistically	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
the	NULL
normal	NULL
individuals	NULL
(	NULL
p	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

RA	NULL
patients	NULL
exhibited	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
that	NULL
overlapped	NULL
with	NULL
those	NULL
of	NULL
normal	NULL
individuals	NULL
,	NULL
albeit	NULL
in	NULL
the	NULL
low	NULL
range	NULL
.	NULL

The	NULL
mean	NULL
level	NULL
of	NULL
NF-KB	NULL
from	NULL
the	NULL
RA	NULL
group	NULL
was	NULL
statistically	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
normal	NULL
individuals	NULL
(	NULL
p	NULL
=	NULL
0.001	NULL
)	NULL
and	NULL
statistically	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
SLE	NULL
patients	NULL
(	NULL
p	NULL
=	NULL
0.01	NULL
)	NULL
.	NULL

NF-KB	NULL
activity	NULL
and	NULL
clinical	NULL
variables	NULL
of	NULL
disease	NULL
activity	NULL
The	NULL
group	NULL
of	NULL
SLE	NULL
patients	NULL
studied	NULL
was	NULL
comprised	NULL
of	NULL
22	NULL
individuals	NULL
with	NULL
SLE	NULL
disease	NULL
activity	NULL
index	NULL
(	NULL
SLEDAT	NULL
)	NULL
levels	NULL
that	NULL
ranged	NULL
from	NULL
0	NULL
to	NULL
32	NULL
.	NULL

Of	NULL
the	NULL
SLE	NULL
patients	NULL
,	NULL
2	NULL
had	NULL
NF-KB	NULL
levels	NULL
within	NULL
1	NULL
SD	NULL
of	NULL
normal	NULL
,	NULL
10	NULL
had	NULL
NF-	NULL
«	NULL
B	NULL
levels	NULL
between	NULL
1	NULL
and	NULL
2	NULL
SD	NULL
,	NULL
and	NULL
10	NULL
had	NULL
SD	NULL
>	NULL
2	NULL
SD	NULL
of	NULL
the	NULL
normal	NULL
mean	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

We	NULL
analyzed	NULL
the	NULL
level	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
with	NULL
respect	NULL
to	NULL
SLEDAI	NULL
by	NULL
regression	NULL
analysis	NULL
and	NULL
found	NULL
that	NULL
there	NULL
was	NULL
no	NULL
correlation	NULL
between	NULL
SLEDAI	NULL
and	NULL
p65	NULL
level	NULL
.	NULL

Since	NULL
corticosteroids	NULL
can	NULL
suppress	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
by	NULL
increasing	NULL
the	NULL
level	NULL
of	NULL
IB	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
it	NULL
was	NULL
important	NULL
to	NULL
determine	NULL
whether	NULL
steroids	NULL
and/or	NULL
other	NULL
drugs	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
lupus	NULL
were	NULL
correlated	NULL
with	NULL
the	NULL
observed	NULL
defect	NULL
in	NULL
NF-KB	NULL
binding	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

The	NULL
abnormalities	NULL
in	NULL
NF-KB	NULL
binding	NULL
activity	NULL
identified	NULL
in	NULL
SLE	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
)	NULL
Normal	NULL
RA1	NULL
SLE4	NULL
SLE14	NULL
J	NULL
p	NULL
o-	NULL
ems	NULL
SB	NULL
CDB	NULL
am	NULL
dit	NULL
an	NULL
cos	NULL
ozs	NULL
ame	NULL
oan	NULL
n	NULL
ous	NULL
Stim	NULL
=	NULL
-	NULL
0	NULL
P	NULL
To	NULL
-	NULL
OP	NULL
OT	NULL
-	NULL
OP	NULL
Normal	NULL
RAZ	NULL
SLE19	NULL
SLE12	NULL
J	NULL
»	NULL
cone	NULL
camus	NULL
ames	NULL
~	NULL
»	NULL
cour	NULL
cues	NULL
snes	NULL
cna	NULL
sim	NULL
ss	NULL
siti	NULL
Ce	NULL
Stim	NULL
0	NULL
-	NULL
P	NULL
To-	NULL
Po	NULL
T	NULL
-	NULL
OP	NULL
T	NULL
-	NULL
-P	NULL
T	NULL
B	NULL
)	NULL
Normal	NULL
RA1	NULL
SLE4	NULL
SLE14	NULL
J	NULL
w.	NULL
``	NULL
lls	NULL
(	NULL
ie	NULL
(	NULL
Gis	NULL
Cle	NULL
Cas	NULL
«	NULL
ee	NULL
Stim	NULL
0	NULL
-	NULL
OP	NULL
T	NULL
-	NULL
P	NULL
T	NULL
-	NULL
P	NULL
T	NULL
-	NULL
P	NULL
T	NULL
Normal	NULL
RAZ	NULL
SLE19	NULL
SLE12	NULL
-~	NULL
@	NULL
&	NULL
@	NULL
«	NULL
«	NULL
came	NULL
Stim	NULL
0	NULL
-	NULL
OP	NULL
T	NULL
-	NULL
P	NULL
T	NULL
-	NULL
P	NULL
T	NULL
-	NULL
P	NULL
T	NULL
C	NULL
)	NULL
Normal	NULL
RA1	NULL
SLE4	NULL
SLE14	NULL
amina	NULL
Alis	NULL
some	NULL
:	NULL
omits	NULL
:	NULL
>	NULL
wt	NULL
sana	NULL
Stim	NULL
--	NULL
P	NULL
T	NULL
-	NULL
P	NULL
T	NULL
-	NULL
P	NULL
T	NULL
.-	NULL
P	NULL
T	NULL
Normal	NULL
RAZ	NULL
SLE19	NULL
SLE12	NULL
Stim	NULL
--	NULL
P	NULL
T	NULL
-	NULL
-P	NULL
T	NULL
.	NULL

-P	NULL
T	NULL
.	NULL

POT	NULL
FIGURE	NULL
5	NULL
.	NULL

Immunoblot	NULL
to	NULL
determine	NULL
the	NULL
protein	NULL
level	NULL
of	NULL
p50	NULL
and	NULL
p65	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
in	NULL
lymphocyte	NULL
extracts	NULL
.	NULL

Lymphocyte	NULL
extracts	NULL
from	NULL
normal	NULL
individuals	NULL
,	NULL
RA	NULL
patients	NULL
,	NULL
and	NULL
SLE	NULL
patients	NULL
were	NULL
separated	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
NFE-	NULL
«	NULL
B-specific	NULL
Ab	NULL
.	NULL

``	NULL
J	NULL
``	NULL
represents	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
.	NULL

Immunoblots	NULL
were	NULL
performed	NULL
with	NULL
15	NULL
ug	NULL
of	NULL
protein	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
unstimulated	NULL
,	NULL
stimulated	NULL
with	NULL
anti-CD3/anti-CD28	NULL
Abs	NULL
(	NULL
T	NULL
)	NULL
,	NULL
or	NULL
PMA/A23187	NULL
(	NULL
P	NULL
)	NULL
.	NULL

A	NULL
,	NULL
A	NULL
specific	NULL
band	NULL
corresponding	NULL
to	NULL
p50	NULL
was	NULL
visualized	NULL
by	NULL
chemiluminescence	NULL
using	NULL
anti-p50	NULL
Ab	NULL
.	NULL

B	NULL
,	NULL
Immunoblot	NULL
was	NULL
performed	NULL
with	NULL
extracts	NULL
isolated	NULL
from	NULL
patients	NULL
,	NULL
as	NULL
decribed	NULL
above	NULL
,	NULL
using	NULL
an	NULL
N	NULL
terminus-specific	NULL
anti-p65	NULL
Ab	NULL
to	NULL
determine	NULL
the	NULL
level	NULL
of	NULL
p65	NULL
in	NULL
lymphocyte	NULL
extracts	NULL
.	NULL

C	NULL
,	NULL
Immunoblot	NULL
was	NULL
performed	NULL
with	NULL
lysates	NULL
to	NULL
measure	NULL
p65	NULL
RelA	NULL
level	NULL
using	NULL
a	NULL
C	NULL
terminus-specific	NULL
anti-p65	NULL
Ab	NULL
.	NULL

patients	NULL
were	NULL
seen	NULL
both	NULL
in	NULL
individuals	NULL
who	NULL
were	NULL
off	NULL
or	NULL
on	NULL
steroids	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

One	NULL
patient	NULL
on	NULL
steroid	NULL
showed	NULL
normal	NULL
NF-KB	NULL
activity	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
RA	NULL
patients	NULL
who	NULL
displayed	NULL
inducible	NULL
NF-KB	NULL
binding	NULL
activity	NULL
,	NULL
there	NULL
was	NULL
no	NULL
correlation	NULL
between	NULL
the	NULL
use	NULL
of	NULL
pred-nisone	NULL
,	NULL
or	NULL
other	NULL
disease-modifying	NULL
agents	NULL
(	NULL
methotrexate	NULL
,	NULL
hydroxy-chloroquin	NULL
,	NULL
azathioprine	NULL
)	NULL
and	NULL
a	NULL
lack	NULL
of	NULL
p65	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Table	NULL
II	NULL
.	NULL

Discussion	NULL
Defective	NULL
production	NULL
of	NULL
IL-2	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
studies	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
SLE	NULL
patients	NULL
from	NULL
different	NULL
investigators	NULL
and	NULL
may	NULL
account	NULL
for	NULL
1687	NULL
A	NULL
)	NULL
SLE	NULL
Normal	NULL
T	NULL
;	NULL
T	NULL
,	NULL
+	NULL
3	NULL
months	NULL
«	NULL
CD3	NULL
acbas	NULL
-	NULL
T	NULL
C	NULL
_-	NULL
-	NULL
+	NULL
+-	NULL
-	NULL
+	NULL
+	NULL
comp	NULL
_-	NULL
t+	NULL
-	NULL
+	NULL
-	NULL
+-	NULL
+	NULL
]	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
»	NULL
na	NULL
Una	NULL
“	NULL
At	NULL
Svi	NULL
B	NULL
)	NULL
C	NULL
-	NULL
&	NULL
-	NULL
-	NULL
Norm	NULL
[	NULL
-	NULL
#	NULL
-	NULL
SLE14	NULL
F	NULL
-	NULL
&	NULL
-	NULL
-	NULL
SLE12	NULL
-	NULL
-e-	NULL
SLE4	NULL
p-	NULL
-__-	NULL
-	NULL
,	NULL
#	NULL
SEs	NULL
3	NULL
K	NULL
stEi6	NULL
1005	NULL
--	NULL
-	NULL
SLE19	NULL
®	NULL
F	NULL
o	NULL
S	NULL
[	NULL
2	NULL
2	NULL
5	NULL
9	NULL
0	NULL
o	NULL
C	NULL
<	NULL
1	NULL
t	NULL
1	NULL
10	NULL
Time	NULL
(	NULL
months	NULL
)	NULL
FIGURE	NULL
6	NULL
.	NULL

The	NULL
level	NULL
of	NULL
NF-KB	NULL
inducibility	NULL
over	NULL
time	NULL
in	NULL
SLE	NULL
patients	NULL
.	NULL

A	NULL
,	NULL
Analysis	NULL
of	NULL
NF-KB	NULL
activity	NULL
in	NULL
extracts	NULL
in	NULL
one	NULL
SLE	NULL
patient	NULL
at	NULL
T	NULL
;	NULL
and	NULL
at	NULL
3	NULL
mo	NULL
after	NULL
T	NULL
;	NULL
.	NULL

B	NULL
,	NULL
Absorbance	NULL
level	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
activity	NULL
derived	NULL
from	NULL
scanned	NULL
autoradiograms	NULL
of	NULL
EMSA	NULL
,	NULL
plotted	NULL
with	NULL
respect	NULL
to	NULL
time	NULL
.	NULL

Six	NULL
SLE	NULL
patients	NULL
were	NULL
analyzed	NULL
over	NULL
different	NULL
time	NULL
periods	NULL
,	NULL
and	NULL
the	NULL
relative	NULL
absorbance	NULL
level	NULL
of	NULL
NF-KB	NULL
is	NULL
shown	NULL
by	NULL
the	NULL
graphed	NULL
lines	NULL
.	NULL

Each	NULL
line	NULL
represents	NULL
the	NULL
p65	NULL
absorbance	NULL
level	NULL
from	NULL
an	NULL
individual	NULL
SLE	NULL
patient	NULL
.	NULL

The	NULL
mean	NULL
relative	NULL
absorbance	NULL
level	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
normals	NULL
is	NULL
presented	NULL
for	NULL
comparison	NULL
(	NULL
-	NULL
-	NULL
-	NULL
-	NULL
)	NULL
.	NULL

impaired	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
NK	NULL
cytotoxicity	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

This	NULL
report	NULL
focuses	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
because	NULL
it	NULL
plays	NULL
an	NULL
integral	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
.	NULL

The	NULL
results	NULL
described	NULL
here	NULL
represent	NULL
the	NULL
first	NULL
focused	NULL
analysis	NULL
of	NULL
the	NULL
regulation	NULL
of	NULL
NF-KB	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
identifies	NULL
a	NULL
defect	NULL
in	NULL
nuclear	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
isolated	NULL
from	NULL
patients	NULL
with	NULL
SLE	NULL
.	NULL

We	NULL
found	NULL
that	NULL
freshly	NULL
isolated	NULL
SLE	NULL
T	NULL
cells	NULL
showed	NULL
a	NULL
TCR-mediated	NULL
defect	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NE-	NULL
«	NULL
B	NULL
.	NULL

This	NULL
defect	NULL
was	NULL
also	NULL
present	NULL
when	NULL
cells	NULL
were	NULL
analyzed	NULL
following	NULL
stimulation	NULL
with	NULL
PMA/A23187	NULL
,	NULL
which	NULL
bypasses	NULL
mem-brane-associated	NULL
signaling	NULL
pathways	NULL
.	NULL

Abs	NULL
specific	NULL
for	NULL
members	NULL
of	NULL
the	NULL
NF-KB	NULL
family	NULL
showed	NULL
that	NULL
the	NULL
defect	NULL
is	NULL
from	NULL
a	NULL
lack	NULL
of	NULL
the	NULL
p65	NULL
RelA	NULL
subunit	NULL
.	NULL

In	NULL
primary	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
predominant	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
are	NULL
p50	NULL
and	NULL
p65	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
p50	NULL
,	NULL
as	NULL
analyzed	NULL
by	NULL
immunoblots	NULL
,	NULL
were	NULL
similar	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
controls	NULL
,	NULL
RA	NULL
controls	NULL
,	NULL
and	NULL
SLE	NULL
patients	NULL
,	NULL
indicating	NULL
that	NULL
not	NULL
all	NULL
NF-	NULL
«	NULL
B/Rel	NULL
components	NULL
are	NULL
abnormal	NULL
and	NULL
the	NULL
defect	NULL
of	NULL
p65SReIA	NULL
accounts	NULL
for	NULL
the	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
1688	NULL
P	NULL
<	NULL
0.0001	NULL
300	NULL
7	NULL
f—ﬁ	NULL
P	NULL
<	NULL
0.01	NULL
(	NULL
O	NULL
N	NULL
aoe	NULL
250	NULL
7	NULL
be	NULL
LJ	NULL
200	NULL
|	NULL
p65	NULL
level	NULL
(	NULL
relative	NULL
absorbance	NULL
)	NULL
*	NULL
s	NULL
&	NULL
150	NULL
7	NULL
143	NULL
pe	NULL
e	NULL
*	NULL
bs	NULL
100	NULL
7	NULL
4	NULL
A	NULL
%	NULL
A	NULL
‘	NULL
€£644	NULL
e	NULL
|	NULL
A	NULL
@	NULL
50	NULL
s	NULL
®	NULL
A	NULL
e	NULL
``	NULL
133.5	NULL
-	NULL
5	NULL
Normal	NULL
RA	NULL
SLE	NULL
N=17	NULL
N=8	NULL
N=22	NULL
FIGURE	NULL
7	NULL
.	NULL

Distribution	NULL
of	NULL
NF-KB	NULL
activity	NULL
.	NULL

The	NULL
absorbance	NULL
level	NULL
corresponding	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
levels	NULL
from	NULL
individuals	NULL
from	NULL
each	NULL
group	NULL
of	NULL
patient	NULL
is	NULL
shown	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
the	NULL
absorbance	NULL
of	NULL
the	NULL
band	NULL
that	NULL
corresponds	NULL
to	NULL
the	NULL
p65	NULL
complex	NULL
on	NULL
EMSA	NULL
from	NULL
the	NULL
same	NULL
exposure	NULL
of	NULL
the	NULL
experimental	NULL
autoradiogram	NULL
.	NULL

Mean	NULL
value	NULL
is	NULL
presented	NULL
,	NULL
and	NULL
the	NULL
perpendicular	NULL
bars	NULL
represent	NULL
+1	NULL
SE	NULL
from	NULL
the	NULL
mean	NULL
.	NULL

abnormal	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
seen	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
.	NULL

Immunoblot	NULL
analyses	NULL
demonstrated	NULL
that	NULL
the	NULL
p65	NULL
subunit	NULL
was	NULL
undetectable	NULL
in	NULL
the	NULL
distinct	NULL
group	NULL
of	NULL
patients	NULL
who	NULL
had	NULL
undetectable	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
on	NULL
EMSA	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
p65	NULL
protein	NULL
was	NULL
confirmed	NULL
using	NULL
Abs	NULL
against	NULL
two	NULL
distinct	NULL
regions	NULL
of	NULL
the	NULL
protein	NULL
,	NULL
indicating	NULL
that	NULL
defective	NULL
expression	NULL
was	NULL
not	NULL
due	NULL
to	NULL
a	NULL
loss	NULL
or	NULL
modification	NULL
of	NULL
a	NULL
specific	NULL
epitope	NULL
.	NULL

The	NULL
immunoblot	NULL
analysis	NULL
also	NULL
excludes	NULL
a	NULL
sequestration	NULL
of	NULL
p65	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
by	NULL
the	NULL
inhibitor	NULL
IkKB	NULL
as	NULL
a	NULL
basis	NULL
for	NULL
the	NULL
decreased	NULL
activity	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
patients	NULL
with	NULL
SLE	NULL
have	NULL
abnormalities	NULL
in	NULL
the	NULL
signaling	NULL
pathway	NULL
at	NULL
the	NULL
nuclear	NULL
level	NULL
.	NULL

Although	NULL
altered	NULL
p65	NULL
NF-KB	NULL
activity	NULL
could	NULL
reflect	NULL
aberrant	NULL
early	NULL
TCR-mediated	NULL
signaling	NULL
(	NULL
4	NULL
)	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
p65	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
following	NULL
stimulation	NULL
with	NULL
PMA/A23187	NULL
argues	NULL
for	NULL
a	NULL
specific	NULL
defect	NULL
in	NULL
NF-KB	NULL
regulation	NULL
independent	NULL
of	NULL
TCR	NULL
Z-chain	NULL
abnormality	NULL
.	NULL

Furthermore	NULL
,	NULL
because	NULL
Z-deficient	NULL
T	NULL
cell	NULL
clones	NULL
are	NULL
partially	NULL
competent	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
signal	NULL
and	NULL
can	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
(	NULL
38	NULL
)	NULL
,	NULL
absence	NULL
of	NULL
the	NULL
Z-chain	NULL
alone	NULL
can	NULL
not	NULL
fully	NULL
account	NULL
for	NULL
the	NULL
defective	NULL
activation	NULL
of	NULL
p65	NULL
in	NULL
some	NULL
patients.Since	NULL
primary	NULL
T	NULL
cells	NULL
require	NULL
NF-KB	NULL
to	NULL
fully	NULL
express	NULL
the	NULL
IL-2	NULL
gene	NULL
,	NULL
the	NULL
defect	NULL
in	NULL
NF-kB	NULL
Table	NULL
I	NULL
.	NULL

_	NULL
NF-KB	NULL
binding	NULL
activity	NULL
is	NULL
independent	NULL
of	NULL
disease	NULL
activity	NULL
NF-	NULL
«	NULL
B	NULL
Binding	NULL
Activity	NULL
(	NULL
absorbance	NULL
)	NULL
SLEDAI	NULL
>	NULL
x	NULL
-	NULL
18D°	NULL
x	NULL
-	NULL
18D	NULL
and	NULL
x	NULL
-	NULL
2SD	NULL
x	NULL
<	NULL
2SD	NULL
0-5	NULL
1	NULL
5	NULL
3	NULL
6-10	NULL
ND	NULL
4	NULL
3	NULL
11-15	NULL
ND	NULL
ND	NULL
2	NULL
16-20	NULL
ND	NULL
1	NULL
2	NULL
>	NULL
21	NULL
1	NULL
ND	NULL
ND	NULL
``	NULL
x	NULL
,	NULL
normal	NULL
mean	NULL
=	NULL
143	NULL
;	NULL
1SD	NULL
=	NULL
62	NULL
.	NULL

*	NULL
Number	NULL
of	NULL
patients	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
ABNORMALITIES	NULL
IN	NULL
HUMAN	NULL
SLE	NULL
Table	NULL
II	NULL
.	NULL

NF-KB	NULL
binding	NULL
activity	NULL
is	NULL
independent	NULL
of	NULL
treatment	NULL
status	NULL
Discase	NULL
Treatment	NULL
N	NULL
NF-B	NULL
(	NULL
mean	NULL
OD	NULL
+	NULL
SEM	NULL
)	NULL
*	NULL
SLE	NULL
No	NULL
steroids	NULL
11	NULL
33.14	NULL
+	NULL
13.99	NULL
Steroids	NULL
11	NULL
33.91	NULL
+	NULL
11.01	NULL
Others	NULL
``	NULL
9	NULL
20.83	NULL
+	NULL
5.64	NULL
Steroids	NULL
+	NULL
others	NULL
``	NULL
4	NULL
25	NULL
+	NULL
13	NULL
RA	NULL
No	NULL
steroids	NULL
2	NULL
70.5	NULL
+	NULL
6.62	NULL
Steroids	NULL
2	NULL
82.5	NULL
+	NULL
7.5	NULL
Others	NULL
``	NULL
6	NULL
68.67	NULL
+	NULL
8.7	NULL
Steroids	NULL
+	NULL
others	NULL
``	NULL
2	NULL
82.5	NULL
+	NULL
7.5	NULL
``	NULL
Hydroxychloroquine	NULL
,	NULL
methotrexate	NULL
,	NULL
and	NULL
azathioprine	NULL
.	NULL

*	NULL
Normal	NULL
mean	NULL
OD	NULL
=	NULL
143	NULL
;	NULL
1SD	NULL
=	NULL
62.	NULL
in	NULL
SLE	NULL
patients	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
previously	NULL
described	NULL
defect	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
.	NULL

In	NULL
the	NULL
patients	NULL
examined	NULL
in	NULL
this	NULL
study	NULL
,	NULL
the	NULL
abnormality	NULL
of	NULL
NF-KB	NULL
did	NULL
not	NULL
correlate	NULL
with	NULL
disease	NULL
activity	NULL
.	NULL

The	NULL
consistent	NULL
inducibility	NULL
of	NULL
the	NULL
p65	NULL
NF-KB	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
that	NULL
seen	NULL
for	NULL
SLE	NULL
patients	NULL
,	NULL
suggests	NULL
that	NULL
the	NULL
pathologic	NULL
mechanism	NULL
for	NULL
NF-KB	NULL
regulation	NULL
differs	NULL
between	NULL
these	NULL
two	NULL
autoimmune	NULL
diseases	NULL
.	NULL

A	NULL
lack	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
,	NULL
particularly	NULL
the	NULL
function	NULL
provided	NULL
by	NULL
the	NULL
p65	NULL
subunit	NULL
that	NULL
contributes	NULL
the	NULL
transcriptional	NULL
activating	NULL
portion	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
complex	NULL
(	NULL
39	NULL
)	NULL
,	NULL
provides	NULL
a	NULL
mechanism	NULL
for	NULL
a	NULL
defect	NULL
in	NULL
IL-2	NULL
expression	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p65	NULL
in	NULL
lupus	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
remaining	NULL
p50	NULL
can	NULL
form	NULL
homodimers	NULL
,	NULL
bind	NULL
DNA	NULL
,	NULL
and	NULL
repress	NULL
gene	NULL
expression	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
p50	NULL
homodimers	NULL
can	NULL
be	NULL
found	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
that	NULL
fail	NULL
to	NULL
produce	NULL
IL-2	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
both	NULL
the	NULL
presence	NULL
of	NULL
p50	NULL
homodimers	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
p65	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
reported	NULL
decreased	NULL
IL-2	NULL
production	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
.	NULL

NE-	NULL
«	NULL
B	NULL
activity	NULL
is	NULL
present	NULL
in	NULL
almost	NULL
all	NULL
cells	NULL
,	NULL
and	NULL
different	NULL
members	NULL
of	NULL
the	NULL
protein	NULL
family	NULL
are	NULL
expressed	NULL
in	NULL
different	NULL
tissues	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Although	NULL
many	NULL
members	NULL
contribute	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
function	NULL
,	NULL
the	NULL
requirement	NULL
for	NULL
multiple	NULL
members	NULL
is	NULL
not	NULL
clear	NULL
,	NULL
but	NULL
one	NULL
could	NULL
speculate	NULL
that	NULL
specificity	NULL
and	NULL
tissue-specific	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
is	NULL
achieved	NULL
through	NULL
assembling	NULL
unique	NULL
combinations	NULL
of	NULL
the	NULL
different	NULL
members	NULL
.	NULL

Genetic	NULL
approaches	NULL
in	NULL
mice	NULL
have	NULL
been	NULL
undertaken	NULL
where	NULL
specific	NULL
NF-	NULL
«	NULL
B	NULL
genes	NULL
were	NULL
disrupted	NULL
through	NULL
a	NULL
knockout	NULL
approach	NULL
to	NULL
determine	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
animal	NULL
to	NULL
survive	NULL
and	NULL
develop	NULL
.	NULL

Although	NULL
a	NULL
lack	NULL
of	NULL
RelA	NULL
leads	NULL
to	NULL
embryonic	NULL
death	NULL
at	NULL
day	NULL
16	NULL
with	NULL
extensive	NULL
apoptosis	NULL
in	NULL
the	NULL
liver	NULL
(	NULL
43	NULL
)	NULL
,	NULL
absence	NULL
of	NULL
the	NULL
smaller	NULL
p50	NULL
subunit	NULL
is	NULL
compatible	NULL
with	NULL
life	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
steroids	NULL
in	NULL
the	NULL
observed	NULL
decrease	NULL
in	NULL
NF-KB	NULL
binding	NULL
activity	NULL
can	NULL
be	NULL
ruled	NULL
out	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
two	NULL
findings	NULL
.	NULL

First	NULL
,	NULL
RA	NULL
patients	NULL
who	NULL
were	NULL
on	NULL
steroids	NULL
displayed	NULL
normal	NULL
level	NULL
of	NULL
NF-kB	NULL
activity	NULL
.	NULL

Second	NULL
,	NULL
NF-KB	NULL
activity	NULL
was	NULL
absent	NULL
in	NULL
patients	NULL
who	NULL
were	NULL
off	NULL
steroids	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
not	NULL
surprising	NULL
in	NULL
light	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
steroids	NULL
may	NULL
actually	NULL
increase	NULL
the	NULL
amount	NULL
of	NULL
inactive	NULL
NF-KB	NULL
,	NULL
as	NULL
IB	NULL
synthesis	NULL
is	NULL
increased	NULL
to	NULL
retain	NULL
NF-KB	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
an	NULL
inactive	NULL
state	NULL
to	NULL
prevent	NULL
nuclear	NULL
translocation	NULL
(	NULL
37	NULL
)	NULL
.	NULL

If	NULL
steroids	NULL
had	NULL
a	NULL
significant	NULL
effect	NULL
,	NULL
then	NULL
immunoblot	NULL
analysis	NULL
would	NULL
reveal	NULL
either	NULL
a	NULL
normal	NULL
level	NULL
of	NULL
p65	NULL
or	NULL
even	NULL
a	NULL
greater	NULL
protein	NULL
level	NULL
.	NULL

However	NULL
,	NULL
this	NULL
finding	NULL
was	NULL
not	NULL
observed	NULL
.	NULL

The	NULL
extent	NULL
to	NULL
which	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
altered	NULL
in	NULL
systemic	NULL
rheumatic	NULL
diseases	NULL
is	NULL
unknown	NULL
.	NULL

In	NULL
this	NULL
communication	NULL
,	NULL
we	NULL
report	NULL
severely	NULL
depressed	NULL
NF-KB	NULL
activity	NULL
in	NULL
SLE	NULL
T	NULL
cells	NULL
and	NULL
moderately	NULL
decreased	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
.	NULL

More	NULL
studies	NULL
are	NULL
needed	NULL
to	NULL
define	NULL
the	NULL
magnitude	NULL
and	NULL
the	NULL
prevalence	NULL
of	NULL
this	NULL
abnormality	NULL
in	NULL
rheumatic	NULL
diseases	NULL
.	NULL

Although	NULL
NF-B	NULL
is	NULL
important	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
many	NULL
genes	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
it	NULL
is	NULL
difficult	NULL
at	NULL
present	NULL
to	NULL
stipulate	NULL
the	NULL
degree	NULL
to	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
which	NULL
its	NULL
deficiency	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
manifold	NULL
immune	NULL
aberrations	NULL
that	NULL
characterize	NULL
lupus	NULL
.	NULL

Along	NULL
this	NULL
line	NULL
,	NULL
it	NULL
should	NULL
be	NULL
considered	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
NF-KB	NULL
activity	NULL
is	NULL
complex	NULL
and	NULL
involves	NULL
the	NULL
contribution	NULL
from	NULL
many	NULL
family	NULL
member	NULL
proteins	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
.	NULL

Lessons	NULL
learned	NULL
from	NULL
knockout	NULL
mice	NULL
may	NULL
not	NULL
directly	NULL
help	NULL
in	NULL
understanding	NULL
the	NULL
role	NULL
of	NULL
decreased	NULL
NF-KB	NULL
activity	NULL
in	NULL
the	NULL
immunopathogenesis	NULL
of	NULL
human	NULL
disease	NULL
.	NULL

For	NULL
example	NULL
,	NULL
a	NULL
lack	NULL
of	NULL
RelB	NULL
,	NULL
although	NULL
it	NULL
does	NULL
not	NULL
cause	NULL
embryonic	NULL
lethality	NULL
,	NULL
is	NULL
associated	NULL
with	NULL
multiorgan	NULL
inflammation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

In	NULL
a	NULL
similar	NULL
context	NULL
,	NULL
IL-2-deficient	NULL
mice	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
what	NULL
one	NULL
may	NULL
expect	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
function	NULL
of	NULL
IL-2	NULL
,	NULL
develop	NULL
a	NULL
severe	NULL
multisys-temic	NULL
inflammatory	NULL
disease	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Apparently	NULL
,	NULL
the	NULL
complexity	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
does	NULL
not	NULL
permit	NULL
direct	NULL
extrapolation	NULL
from	NULL
murine	NULL
models	NULL
to	NULL
human	NULL
disease	NULL
.	NULL

Therefore	NULL
,	NULL
further	NULL
studies	NULL
are	NULL
needed	NULL
to	NULL
investigate	NULL
the	NULL
function	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
human	NULL
systemic	NULL
autoimmune	NULL
diseases	NULL
and	NULL
,	NULL
specifically	NULL
,	NULL
how	NULL
its	NULL
defect	NULL
contributes	NULL
to	NULL
decreased	NULL
IL-2	NULL
production	NULL
.	NULL

Acknowledgment	NULL
We	NULL
thank	NULL
Scott	NULL
Bowden	NULL
for	NULL
technical	NULL
assistance	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Tsokos	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
B.	NULL
Kovacs	NULL
,	NULL
and	NULL
S.	NULL
N.	NULL
Liossis	NULL
.	NULL

1997	NULL
.	NULL

Lymphocytes	NULL
,	NULL
cytokines	NULL
,	NULL
inflammation	NULL
,	NULL
and	NULL
immune	NULL
trafficking	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Rheum	NULL
.	NULL

9:380	NULL
.	NULL

2	NULL
.	NULL

Liossis	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
P.	NULL
P.	NULL
Sfikakis	NULL
,	NULL
and	NULL
G.	NULL
C.	NULL
Tsokos	NULL
.	NULL

1998	NULL
.	NULL

Immune	NULL
cell	NULL
signaling	NULL
aberrations	NULL
in	NULL
human	NULL
lupus	NULL
.	NULL

Immunol	NULL
.	NULL

Res	NULL
.	NULL

18:27	NULL
.	NULL

3	NULL
.	NULL

Vassilopoulos	NULL
,	NULL
D.	NULL
,	NULL
B.	NULL
Kovacs	NULL
,	NULL
and	NULL
G.	NULL
C.	NULL
Tsokos	NULL
.	NULL

1995	NULL
.	NULL

TCR/CD3	NULL
complex-mediated	NULL
signal	NULL
transduction	NULL
pathway	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:2269	NULL
.	NULL

4	NULL
.	NULL

Liossis	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
X	NULL
.	NULL

Z.	NULL
Ding	NULL
,	NULL
G.	NULL
J.	NULL
Dennis	NULL
,	NULL
and	NULL
G.	NULL
C.	NULL
Tsokos	NULL
.	NULL

1998	NULL
.	NULL

Altered	NULL
pattern	NULL
of	NULL
TCR/CD3-mediated	NULL
protein-tyrosyl	NULL
phosphorylation	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
deficient	NULL
expression	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
£-chain	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

101:1448	NULL
.	NULL

5	NULL
.	NULL

Dayal	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Kammer	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
T	NULL
cell	NULL
enigma	NULL
in	NULL
lupus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

39:23	NULL
.	NULL

6	NULL
.	NULL

Kammer	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
I.	NULL
U.	NULL
Khan	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kammer	NULL
,	NULL
I.	NULL
Olorenshaw	NULL
,	NULL
and	NULL
D.	NULL
Mathis	NULL
.	NULL

1996	NULL
.	NULL

Deficient	NULL
type	NULL
I	NULL
protein	NULL
kinase	NULL
A	NULL
isozyme	NULL
activity	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
T	NULL
lymphocytes	NULL
:	NULL
II	NULL
.	NULL

Abnormal	NULL
isozyme	NULL
kinetics	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:2690	NULL
.	NULL

7	NULL
.	NULL

Kammer	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
I.	NULL
U.	NULL
Khan	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Malemud	NULL
.	NULL

1994	NULL
.	NULL

Deficient	NULL
type	NULL
I	NULL
protein	NULL
kinase	NULL
A	NULL
isozyme	NULL
activity	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:422	NULL
.	NULL

8	NULL
.	NULL

Koshy	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Berger	NULL
,	NULL
and	NULL
M.	NULL
K.	NULL
Crow	NULL
.	NULL

1996	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
CD40	NULL
ligand	NULL
on	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

98:826	NULL
.	NULL

9	NULL
.	NULL

Desai-Mchta	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
Lu	NULL
,	NULL
R.	NULL
Ramsey-Goldman	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Datta	NULL
.	NULL

1996	NULL
.	NULL

Hyperex-pression	NULL
of	NULL
CD40	NULL
ligand	NULL
by	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
in	NULL
human	NULL
lupus	NULL
and	NULL
its	NULL
role	NULL
in	NULL
pathogenic	NULL
autoantibody	NULL
production	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

97:2063	NULL
.	NULL

10	NULL
.	NULL

Kovacs	NULL
,	NULL
B.	NULL
,	NULL
S.	NULL
N.	NULL
Liossis	NULL
,	NULL
G.	NULL
J.	NULL
Dennis	NULL
,	NULL
and	NULL
G.	NULL
C.	NULL
Tsokos	NULL
.	NULL

1997	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
functional	NULL
Fas-ligand	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Autoimmunity	NULL
25:213	NULL
.	NULL

11	NULL
.	NULL

Stohl	NULL
,	NULL
W.	NULL
1995	NULL
.	NULL

Impaired	NULL
polyclonal	NULL
T	NULL
cell	NULL
cytolytic	NULL
activity	NULL
:	NULL
a	NULL
possible	NULL
risk	NULL
factor	NULL
for	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

38:506	NULL
.	NULL

12	NULL
.	NULL

Ohtsuka	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
D.	NULL
Gray	NULL
,	NULL
M.	NULL
M.	NULL
Stimmler	NULL
,	NULL
B.	NULL
Toro	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Horwitz	NULL
.	NULL

1998	NULL
.	NULL

Decreased	NULL
production	NULL
of	NULL
TGF-B	NULL
by	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:2539	NULL
.	NULL

13	NULL
.	NULL

Kovacs	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
Vassilopoulos	NULL
,	NULL
S.	NULL
A.	NULL
Vogelgesang	NULL
,	NULL
and	NULL
G.	NULL
C.	NULL
Tsokos	NULL
.	NULL

1996	NULL
.	NULL

Defective	NULL
CD3-mediated	NULL
cell	NULL
death	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
role	NULL
of	NULL
decreased	NULL
intracellular	NULL
TNF-a	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Im-munopathol	NULL
.	NULL

81:293	NULL
.	NULL

14	NULL
.	NULL

Alcocer-Varela	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
D.	NULL
Alarcon-Segovia	NULL
.	NULL

1982	NULL
.	NULL

Decreased	NULL
production	NULL
of	NULL
and	NULL
response	NULL
to	NULL
interleukin-2	NULL
by	NULL
cultured	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

69:1388	NULL
.	NULL

15.	NULL
de	NULL
Faucal	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Godard	NULL
,	NULL
M.	NULL
A.	NULL
Peyrat	NULL
,	NULL
J.	NULL
F.	NULL
Moreau	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Soulillou	NULL
.	NULL

1984	NULL
.	NULL

Impaired	NULL
IL-2	NULL
production	NULL
by	NULL
lymphocytes	NULL
of	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Ann	NULL
.	NULL

Immunol	NULL
.	NULL

135:161	NULL
.	NULL

16	NULL
.	NULL

Linker-Isracli	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
C.	NULL
Bakke	NULL
,	NULL
R.	NULL
C.	NULL
Kitridou	NULL
,	NULL
S.	NULL
Gendler	NULL
,	NULL
S.	NULL
Gillis	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Horwitz	NULL
.	NULL

1983	NULL
.	NULL

Defective	NULL
production	NULL
of	NULL
interleukin	NULL
1	NULL
and	NULL
interleukin	NULL
2	NULL
in	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
(	NULL
SLE	NULL
)	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

130:2651	NULL
.	NULL

17	NULL
.	NULL

Murakawa	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Takada	NULL
,	NULL
Y.	NULL
Ueda	NULL
,	NULL
N.	NULL
Suzuki	NULL
,	NULL
T.	NULL
Hoshino	NULL
,	NULL
and	NULL
T.	NULL
Sakane	NULL
.	NULL

1985	NULL
.	NULL

Characterization	NULL
of	NULL
T	NULL
lymphocyte	NULL
subpopulations	NULL
responsible	NULL
for	NULL
deficient	NULL
interleukin	NULL
2	NULL
activity	NULL
in	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

134	NULL
;	NULL
187	NULL
.	NULL

18	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
D.	NULL
Straus	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1993	NULL
.	NULL

Signal	NULL
transduction	NULL
events	NULL
leading	NULL
to	NULL
T-cell	NULL
lymphokine	NULL
gene	NULL
expression	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
14:357	NULL
.	NULL

19	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Loh	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7:333	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

1689	NULL
Rothenberg	NULL
,	NULL
E.	NULL
V.	NULL
,	NULL
and	NULL
S.	NULL
B	NULL
.	NULL

Ward	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
dynamic	NULL
assembly	NULL
of	NULL
diverse	NULL
transcription	NULL
factors	NULL
integrates	NULL
activation	NULL
and	NULL
cell-type	NULL
information	NULL
for	NULL
interleukin	NULL
2	NULL
gene	NULL
regulation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:9358	NULL
.	NULL

Berridge	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1997	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
in	NULL
health	NULL
and	NULL
disease	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

17:155	NULL
.	NULL

Kalli	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Huntoon	NULL
,	NULL
M.	NULL
Bell	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
McKean	NULL
.	NULL

1998	NULL
.	NULL

Mechanism	NULL
responsible	NULL
for	NULL
T-cell	NULL
antigen	NULL
receptor-	NULL
and	NULL
€D28-	NULL
or	NULL
interleukin	NULL
1	NULL
(	NULL
IL-1	NULL
)	NULL
receptor-initiated	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
by	NULL
NF-kB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:3140	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
Nolan	NULL
.	NULL

1991	NULL
.	NULL

Nuclear	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
elements	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
:	NULL
induction	NULL
requirements	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:2734	NULL
.	NULL

McGuire	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
and	NULL
M.	NULL
Iacobelli	NULL
.	NULL

1997	NULL
.	NULL

Involvement	NULL
of	NULL
Rel	NULL
,	NULL
Fos	NULL
,	NULL
and	NULL
Jun	NULL
proteins	NULL
in	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
IL-	NULL
2	NULL
promoter	NULL
CD28	NULL
response	NULL
element/AP-1	NULL
sequence	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:1319	NULL
.	NULL

Hughes	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pober	NULL
.	NULL

1996	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
in	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
:	NULL
convergence	NULL
of	NULL
costimulatory	NULL
signals	NULL
and	NULL
differences	NULL
from	NULL
transformed	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:5369	NULL
.	NULL

Maggirwar	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
E.	NULL
W.	NULL
Harhaj	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Sun	NULL
.	NULL

1997	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
CD28-responsive	NULL
element	NULL
by	NULL
NF-ATp	NULL
and	NULL
various	NULL
NF-B/Re	NULL
!	NULL

transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:2605	NULL
.	NULL

Lai	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
G.	NULL
Horvath	NULL
,	NULL
J.	NULL
Subleski	NULL
,	NULL
J.	NULL
Bruder	NULL
,	NULL
P.	NULL
Ghosh	NULL
,	NULL
and	NULL
T.	NULL
H.	NULL
Tan	NULL
.	NULL

1995	NULL
.	NULL

RelA	NULL
is	NULL
a	NULL
potent	NULL
transcriptional	NULL
activator	NULL
of	NULL
the	NULL
CD28	NULL
response	NULL
element	NULL
within	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:4260	NULL
.	NULL

Musso	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Ghiorzo	NULL
,	NULL
P.	NULL
Fiorentini	NULL
,	NULL
R.	NULL
Giuffrida	NULL
,	NULL
P.	NULL
Ciotti	NULL
,	NULL
C.	NULL
Garre	NULL
,	NULL
R.	NULL
Ravazzolo	NULL
,	NULL
and	NULL
G.	NULL
Bianchi-Scarra	NULL
.	NULL

1996	NULL
.	NULL

An	NULL
upstream	NULL
positive	NULL
regulatory	NULL
element	NULL
in	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
is	NULL
recognized	NULL
by	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

family	NULL
members	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

223:64	NULL
.	NULL

Shannon	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
S.	NULL
R.	NULL
Himes	NULL
,	NULL
and	NULL
L.	NULL
S.	NULL
Coles	NULL
.	NULL

1995	NULL
.	NULL

GM-CSF	NULL
and	NULL
IL-2	NULL
share	NULL
common	NULL
control	NULL
mechanisms	NULL
in	NULL
response	NULL
to	NULL
costimulatory	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

57:767	NULL
.	NULL

Delphin	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
J.	NULL
Stavnezer	NULL
.	NULL

1995	NULL
.	NULL

Characterization	NULL
of	NULL
an	NULL
interleukin	NULL
4	NULL
(	NULL
IL-4	NULL
)	NULL
responsive	NULL
region	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
germline	NULL
epsilon	NULL
promoter	NULL
:	NULL
regulation	NULL
by	NULL
NF-	NULL
IL-4	NULL
,	NULL
a	NULL
C/EBP	NULL
family	NULL
member	NULL
and	NULL
NF-	NULL
«	NULL
B/p50	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:181	NULL
.	NULL

Kasibhatla	NULL
,	NULL
S.	NULL
,	NULL
L.	NULL
Genestier	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1999	NULL
.	NULL

Regulation	NULL
of	NULL
Fas-ligand	NULL
expression	NULL
during	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
lymphocytes	NULL
via	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274:987	NULL
.	NULL

Attar	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
J.	NULL
Caamano	NULL
,	NULL
D.	NULL
Carrasco	NULL
,	NULL
V.	NULL
Iotsova	NULL
,	NULL
H.	NULL
Ishikawa	NULL
,	NULL
R.	NULL
P.	NULL
Ryseck	NULL
,	NULL
F.	NULL
Weih	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1997	NULL
.	NULL

Genetic	NULL
approaches	NULL
to	NULL
study	NULL
Rel/NF-	NULL
«	NULL
B/I	NULL
xB	NULL
function	NULL
in	NULL
mice	NULL
.	NULL

Semin	NULL
.	NULL

Cancer	NULL
Biol	NULL
.	NULL

8:93	NULL
.	NULL

Harlow	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
D.	NULL
Lane	NULL
.	NULL

1988	NULL
.	NULL

Antibodies	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Plainview	NULL
.	NULL

Andrews	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
V.	NULL
Paller	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
rapid	NULL
micropreparation	NULL
technique	NULL
for	NULL
extraction	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
from	NULL
limiting	NULL
numbers	NULL
of	NULL
mammalian	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:2499	NULL
.	NULL

May	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
S.	NULL
Ghosh	NULL
.	NULL

1997	NULL
.	NULL

Rel/NF-	NULL
«	NULL
B	NULL
and	NULL
I	NULL
«	NULL
B	NULL
proteins	NULL
:	NULL
an	NULL
overview	NULL
.	NULL

Semin	NULL
.	NULL

Cancer	NULL
Biol	NULL
.	NULL

8:63	NULL
.	NULL

Scheinman	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
P.	NULL
C.	NULL
Cogswell	NULL
,	NULL
A.	NULL
K.	NULL
Lofquist	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1995	NULL
.	NULL

Role	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
in	NULL
mediation	NULL
of	NULL
immunosuppression	NULL
by	NULL
glucocorticoids	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Science	NULL
270:283	NULL
.	NULL

Auphan	NULL
,	NULL
N.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
DiDonato	NULL
,	NULL
C.	NULL
Rosette	NULL
,	NULL
A.	NULL
Helmberg	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Immunosuppression	NULL
by	NULL
glucocorticoids	NULL
:	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
activity	NULL
through	NULL
induction	NULL
of	NULL
IB	NULL
synthesis	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Science	NULL
270:286	NULL
.	NULL

Sussman	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
J.	NULL
S.	NULL
Bonifacino	NULL
,	NULL
J.	NULL
Lippincott-Schwartz	NULL
,	NULL
A.	NULL
M.	NULL
Weissman	NULL
,	NULL
T.	NULL
Saito	NULL
,	NULL
R.	NULL
D.	NULL
Klausner	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell	NULL
.	NULL

1988	NULL
.	NULL

Failure	NULL
to	NULL
synthesize	NULL
the	NULL
T	NULL
cell	NULL
CD3-£	NULL
chain	NULL
:	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
a	NULL
partial	NULL
T	NULL
cell	NULL
receptor	NULL
complex	NULL
.	NULL

Cell	NULL
52:85	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
E.	NULL
P.	NULL
Dixon	NULL
,	NULL
N.	NULL
J.	NULL
Peffer	NULL
,	NULL
H.	NULL
Bogerd	NULL
,	NULL
S.	NULL
Doetre	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
65-kDa	NULL
subunit	NULL
of	NULL
human	NULL
NF-KB	NULL
functions	NULL
as	NULL
a	NULL
potent	NULL
transcriptional	NULL
activator	NULL
and	NULL
a	NULL
target	NULL
for	NULL
v-Rel-mediated	NULL
repression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1875	NULL
.	NULL

Baer	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Dillner	NULL
,	NULL
R.	NULL
C.	NULL
Schwartz	NULL
,	NULL
C.	NULL
Sedon	NULL
,	NULL
S.	NULL
Nedospasov	NULL
,	NULL
and	NULL
P.	NULL
F.	NULL
Johnson	NULL
.	NULL

1998	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
transcription	NULL
in	NULL
macrophages	NULL
is	NULL
attenuated	NULL
by	NULL
an	NULL
autocrine	NULL
factor	NULL
that	NULL
preferentially	NULL
induces	NULL
NF-kB	NULL
p50	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:5678	NULL
.	NULL

Sundstedt	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Sigvardsson	NULL
,	NULL
T.	NULL
Leanderson	NULL
,	NULL
G.	NULL
Hedlund	NULL
,	NULL
T.	NULL
Kalland	NULL
,	NULL
and	NULL
M.	NULL
Dohisten	NULL
.	NULL

1996	NULL
.	NULL

In	NULL
vivo	NULL
anergized	NULL
CD4*	NULL
T	NULL
cells	NULL
express	NULL
perturbed	NULL
AP-1	NULL
and	NULL
NF-KB	NULL
transcription	NULL
factors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:979	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
1996	NULL
.	NULL

The	NULL
NF-KB	NULL
and	NULL
IB	NULL
proteins	NULL
:	NULL
new	NULL
discoveries	NULL
and	NULL
insights	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:649	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
W.	NULL
C.	NULL
Sha	NULL
,	NULL
R.	NULL
T.	NULL
Bronson	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1995	NULL
.	NULL

Embryonic	NULL
lethality	NULL
and	NULL
liver	NULL
degeneration	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
RelA	NULL
component	NULL
of	NULL
NF-B	NULL
.	NULL

Nature	NULL
376:167.	NULL
.	NULL

Sha	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
H.	NULL
C.	NULL
Liou	NULL
,	NULL
E.	NULL
I.	NULL
Tuomanen	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1995	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-KB	NULL
leads	NULL
to	NULL
multifocal	NULL
defects	NULL
in	NULL
immune	NULL
responses	NULL
.	NULL

Cell	NULL
80:321	NULL
.	NULL

Horak	NULL
,	NULL
I	NULL
.	NULL

1995	NULL
.	NULL

Immunodeficiency	NULL
in	NULL
IL-2-knockout	NULL
mice	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Im-munopathol	NULL
.	NULL

76:8172	NULL
.	NULL

Contractor	NULL
,	NULL
N.	NULL
V.	NULL
,	NULL
H.	NULL
Bassiri	NULL
,	NULL
T.	NULL
Reya	NULL
,	NULL
A.	NULL
Y	NULL
.	NULL

Park	NULL
,	NULL
D.	NULL
C.	NULL
Baumgart	NULL
,	NULL
M.	NULL
A.	NULL
Wasik	NULL
,	NULL
S.	NULL
G.	NULL
Emerson	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Carding	NULL
.	NULL

1998	NULL
.	NULL

Lymphoid	NULL
hyperplasia	NULL
,	NULL
autoimmunity	NULL
,	NULL
and	NULL
compromised	NULL
intestinal	NULL
intraepithelial	NULL
lymphocyte	NULL
development	NULL
in	NULL
colitis-free	NULL
gnotobiotic	NULL
IL-2-deficient	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:385	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

